Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
1 Abbreviated Title:  CAPOX Pembrolizumab in BTC  
CC Protocol #:  17C0082 G 
Version Date:  03/19/2020 
Study ID: [REMOVED] 
Title: A Phase 2 S tudy of Pembrolizumab, a Monoclonal Antibody A gainst PD -1, in 
Combination with C apecitabine and O xaliplatin  (CAP OX) in  Subjects  with Advanced B iliary 
Tract C arcinoma (BTC)  
 NCI Principal Investigator:         Tim Greten, MD  
 
     Thoracic & GI Malignancies  Branch  
     National Cancer Institute  
     Building 10, Room 2B38B 
     9000 Rockville Pike      Bethesda,  MD 2 0892 
     240-760-6114       gretentf@mail.nih.gov
  
 
Investigational Agents:     
None Commercial  Agents :  
Pembrolizumab (Keytruda) Capecitabine  
Oxaliplatin  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
2 PRÉCIS  
Background:  
• The most compelling argument in favor of testing immune -based strategies (and anti -PD1 
therapy ) in biliary tract cancers (BTC) is that chronic inflammation appears to be the 
most common etiologic factor in the  development of biliary tract cancer.  
• Single- agent activity has been shown  for PD1-directed therapy in  BTC.  Given the 
potential for oxaliplatin -induced immunogenic cell death we would like to evaluate the 
combination of CAPOX chemotherapy with pembrolizumab.  
Objective:  
• To determine the 5 -month PFS of Pembrolizumab in combi natio n with CAP OX in 
patients with advanced biliary tract carcinoma.  
Eligibility:  
• Histologically confirmed diagnosis biliary tract carcinoma  OR histopathological 
confirmation of carcinoma in the setting of clinical and radiological characteristics which, 
together wi th th e pathology, are highly suggestive of a diagnosis of biliary tract 
carcinoma.  
• Patients must have at least one prior chemotherapeutic regimen.  
• Patients must have disease that is not amenable to potentially curative resection . 
• No prior treatment w ith oxalip latin. 
Design:  
• The proposed study is a phase II study of Pembrolizumab in combination with CAPOX in patients with advanced biliary tract carcinoma.  
 
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
3 TABLE OF CONTENTS   
PRÉCIS  .......................................................................................................................................... 2  
TABLE OF CONTENTS  ................................................................................................................ 3  
1. INTRODUCTION  .................................................................................................................. 8  
1.1 Study Objectives .............................................................................................................. 8  
1.1.1  Primary Objective:  .................................................................................................... 8  
1.1.2  Secondary Objectives:  .............................................................................................. 8  
1.1.3  Exploratory Objectives: ............................................................................................ 8  
1.2 Background and Rationale ............................................................................................... 8  
1.2.1  Biliary tract cancer/Cholangiocarcinoma: current standard of care.  ........................ 8  
1.2.2  Immune-based approaches in gastrointestinal malignancies .................................... 9  
1.2.3  Inflammation and predisposition to biliary tract carcinoma.  .................................. 10  
1.2.4  Immunogenicity of biliary tract carcinoma.  ............................................................ 10  
1.2.5  Translational immune -based efforts in BTC ........................................................... 13  
1.2.6  Pembrolizumab  ....................................................................................................... 15  
1.2.7  Rationale for Dose Selection/Reg imen/Modification  ............................................. 17  
1.2.8  CAPOX in biliary tract carcinomas  ........................................................................ 18  
2 ELIGBILITY ASSESSMENT AND ENROLLMENT  ........................................................ 18  
2.1 Eligibility Criteria  .......................................................................................................... 18  
2.1.1  Inclusion Criteria  .................................................................................................... 18  
2.1.2  Exclusion Criteria  ................................................................................................... 19  
2.1.3  Recruitment Strategies  ............................................................................................ 20  
2.2 Screening Evaluation ...................................................................................................... 20  
2.3 Registration Procedures.................................................................................................. 21  
2.3.1  Treatment Assignment Procedures (For registration purposes only): .................... 21  
2.4 Baseline Evaluation  ........................................................................................................ 22  
3 STUDY IMPLEMENTATION  ............................................................................................ 22  
3.1 Study Design .................................................................................................................. 22  
3.2 Schedule ......................................................................................................................... 23  
3.3 Drug Administration  ...................................................................................................... 23  
3.3.1  Pembrolizumab  ....................................................................................................... 23  
3.3.2  CAPOX ................................................................................................................... 23  
3.4 Dosing Delays and Modifications .................................................................................. 24  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
4 3.4.1  General guidance  .................................................................................................... 24  
3.4.2  Dose Modifications for Hematologic Toxicity ....................................................... 24  
3.4.3  Dose Modifications for Neutropenia for Capecitabine and Oxaliplatin ................. 24  
Grade 2  ...................................................................................................................................... 24  
1.0 ≤ ANC < 1.5 x 109/L  .......................................................................................................... 24  
Platelets > 50 - < 75 x 109/L  ..................................................................................................... 24  
Grade 3  ...................................................................................................................................... 24  
0.5 ≤ ANC < 1.0 x 109/L  .......................................................................................................... 24  
3.4.4  Capecitabine  ............................................................................................................ 25  
3.4.5  Oxaliplatin ............................................................................................................... 25  
3.4.6  Pembrolizumab  ....................................................................................................... 26  
3.5 Study Calendar ............................................................................................................... 31  
3.6 Criteria for Removal from Protocol Therapy and Off Study Criteria ............................ 33  
3.6.1  Criteria for Removal from Protocol Therapy.......................................................... 33  
3.6.2  Off-Study Criteria  ................................................................................................... 33  
3.6.3  Off-Study Procedure ............................................................................................... 34  
4 CONCOMITANT MEDICATIONS/MEASURES  .............................................................. 34  
4.1 Supportive Care Guidelines ........................................................................................... 34  
4.1.1  Pneumonitis: ........................................................................................................... 34  
4.1.2  Diarrhea/Colitis  ....................................................................................................... 34  
4.1.3  Type 1 diabetes mellitus  ......................................................................................... 35  
4.1.4  Hypophysitis ........................................................................................................... 35  
4.1.5  Hepatic  .................................................................................................................... 36  
4.1.6  Renal Failure or Nephritis  ....................................................................................... 36  
5 BIOSPECIMEN COLLECTION  .......................................................................................... 37  
5.1 Correlative Studies for Research  .................................................................................... 37  
5.2 NCI Correlative  Studies ................................................................................................. 38  
5.2.1  Immune monitoring ................................................................................................ 38  
5.2.2  Tumor Biopsy ......................................................................................................... 39  
5.2.3  Tumor tissue analysis .............................................................................................. 39  
5.3 Sample Storage, Tracking and Disposition .................................................................... 40  
5.3.1  Samples Managed by Dr. Figg’s Blood Processing Core (BPC)............................ 40  
5.3.2  Procedures for Storage of Tissue Specimens in the Laboratory of Pathology ....... 41  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
5 5.3.3  Procedures for storage of specimens in the Laboratory of Dr. Greten ................... 41  
5.3.4  Protocol Completion/Sample Destruction  .............................................................. 42  
5.4 Samples for Genetic/Genomic Analysis  ........................................................................ 42  
5.4.1  Privacy and Confidentiality of medical information/biological specimens ............ 42  
5.4.2  Management of Results ........................................................................................... 42  
6 DATA COLLECTION AND EVALUATION  ..................................................................... 42  
6.1 Data Collection  ............................................................................................................... 42  
6.2 Data Sharing Plans  ......................................................................................................... 43  
6.2.1  Human Data Sharing Plan ....................................................................................... 43  
6.2.2  Genomic Data Sharing  Plan  .................................................................................... 43  
6.3 Response Criteria  ........................................................................................................... 44  
6.3.1  Definitions ............................................................................................................... 44  
6.3.2  Disease Parameters  ................................................................................................. 44  
6.3.3  Methods for Evaluation of Measurable Disease  ..................................................... 45  
6.3.4  Response Criteria  .................................................................................................... 47  
6.3.5  Duration of Response .............................................................................................. 49  
6.4 Modified immune- related response criteria (irRC)  ........................................................ 49  
6.5 Toxicity Criteria  ............................................................................................................. 49  
7 NIH REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN  .... 50  
7.1 Definitions  ...................................................................................................................... 50  
7.2 OHSRP Office of Compliance and Training / IRB Reporting ....................................... 50  
7.2.1  Expedited Reporting ............................................................................................... 50  
7.2.2  IRB Requirements for PI Reporting at Continuing Review ................................... 50  
7.3 NCI Clinical Director Reporting  .................................................................................... 50  
7.4 NIH Required Data and Safety Monitoring Plan ........................................................... 50  
7.5 Safety Reporting Criteria to the Pharmaceutical Collaborator (Merck)  ........................ 50  
7.5.1  Auditing and Monitoring. ....................................................................................... 50  
7.5.2  Safety Reports.  ........................................................................................................ 51  
8 STATISTICAL CONSIDERATIONS .................................................................................. 51  
9 COLLABORATIVE AGREEMENTS  ................................................................................. 52  
9.1 Coopera tive Research and Development Agreement (CRADA)  ................................... 52  
9.2 Material Transfer Agreement  ......................................................................................... 52  
10 HUMAN SUBJECTS PROTECTIONS  ............................................................................... 52  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
6 10.1  Rationale For Subject Selection  ................................................................................. 52  
10.2  Participation of Children ............................................................................................ 52  
10.3  Participation of subjects unable to give consent ......................................................... 52  
10.4  Evaluation of Benefits and Risks/Discomforts for all participants  ............................ 53  
10.4.1  Risk of Optional Biopsy.......................................................................................... 53  
10.4.2  Risks of exposure to ionizing radiation .................................................................. 53  
10.4.3  Research Blood Collection Risks............................................................................ 53  
10.4.4  Other Risks.............................................................................................................. 53  
10.4.5  Benefits  ................................................................................................................... 53  
10.5  Consent Process and Documentation ......................................................................... 53  
10.5.1  Re-Consent via Telephone ...................................................................................... 53  
11 PHARMACEUTICAL INFORMATION  ............................................................................. 54  
11.1  Pembrolizumab  ........................................................................................................... 54  
11.1.1  Packaging and L abeling Information  ...................................................................... 54  
11.1.2  Stability and Handling of Drug Product ................................................................. 55  
11.1.3  Clinical Supplies Disclosure  ................................................................................... 55  
11.1.4  Storage and Handling Requirements ...................................................................... 56  
11.1.5  Returns and Reconciliation ..................................................................................... 56  
11.2  Oxaliplatin  .................................................................................................................. 56  
11.2.1  Toxicity  ................................................................................................................... 56  
11.2.2  Formulation  ............................................................................................................. 57  
11.2.3  Preparation  .............................................................................................................. 57  
11.2.4  General  .................................................................................................................... 58  
11.2.5  Stability and Storage ............................................................................................... 58  
11.2.6  Administration procedures ...................................................................................... 58  
11.2.7  Incompatibilities  ..................................................................................................... 59  
11.3  CAPECITABINE  ....................................................................................................... 59  
11.3.1  Source ..................................................................................................................... 59  
11.3.2  Toxicity  ................................................................................................................... 59  
11.3.3  Formulation and preparation ................................................................................... 61  
11.3.4  Stability and Storage ............................................................................................... 61  
11.3.5  Administration procedures ...................................................................................... 61  
11.3.6  Incompatibilities  ..................................................................................................... 62  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
7 12 REFERENCES  ..................................................................................................................... 63  
13 APPENDICES  ...................................................................................................................... 69  
13.1  Appendix A- Performance Status Criteria  ................................................................... 69  
13.2  Appendix B- Modified Immune -Related Response Criteria (irRC)  ........................... 70  
13.3  Appendix C PATIENT’S MEDICATION DIARY ________________________... 72  
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
8  
1. INTRODUCTION 
1.1 STUDY OBJECTIVES  
1.1.1 Primar y Objective:  
• To determ ine the 5 -month PFS of Pembrolizumab in combination with capecitabine and 
oxaliplatin chemotherapy ( CAPOX) in patients with advanced biliary tract carcinoma.  
1.1.2 Secondary Objectives : 
• To determine the safety, tolerability and feasibility of Pembrolizumab in combination 
with capecitabine and oxaliplatin chem otherapy (CAPOX) in patients with advanced 
biliary tract carcinoma.  
• To evaluate the response rate and overall survival in patients with advanced biliary tract cancer during and following treatment with Pembro lizumab in combination with 
capecitabine and oxaliplatin chemotherapy (CAPOX) in patients with a dvan ced biliary 
tract carcinoma.  
1.1.3 Exploratory Objectives:  
• To measure changes in PDL1 expression in the tumors of patients with advanced bil iary 
tract cancer foll owing treatment with capecitabine and oxaliplatin chemotherapy 
(CAPOX) in patients with advanced bil iary tract carcinoma.  
• To measure changes in immune parameters in the peripheral blood and tumors in patients with advanced biliary tract cancer following tr eatment with Pembrolizumab in 
combination with capecitabine and oxaliplatin chemotherapy (CAPOX)  in patients with 
advanced biliary tract carcinoma.  
1.2 B
ACKGROUND AND RATIONALE  
1.2.1 Biliary tract cancer/Cholangiocarcinoma: current standard of care.  
The term biliary  tract carcinoma (BTC) refers primarily to cance rs which develop in the 
gallbladder and intra - and extra-hepatic biliary ductal system, although periampullary tumors are 
often considered part of this group as well. BTC is a relatively uncommon diagnosis, a nd 
randomized studies are few and far between. A mong the new cases of BTC that are diagnosed 
every y ear in the United States, there are approximately 6500 cases of gallbladder carcinoma, 
3000 cases of extrahepatic cholangiocarcinoma, and 3000 cases of intr ahepatic 
cholangiocarcinoma[ 1].  
As is the case for most solid tumors , surgical resection is the only curative approach for patients 
with BTC, although recurrence rates are high and the majority of patients who initially present with the disease are not resectable. Patients with periampullary tumors or extrahepatic cholangioca rcinomas commonly present with localized disease  – primarily because of the early 
development of jaundice – and are more likely to be operable. In contrast, complete surgical 
resection of intrahepatic cholangiocarcinomas is rarely feasible with clear margi ns. Gallbladder 
carcinoma is frequently identified i ncidentally at the time of cholecystectomy for presumed 
cholelithiasis, in which case re -exploration and further extended resection is  usually advised[ 2
]. 
For me tastatic or unresectable disease the modest standard of care for BTC comprises 
gemcitabine in combination with cisplatin chemotherapy, based on the ABC -02 trial  in which a 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
9 total of 410 patients with unresecta ble locally advanced or metastatic disease were rand omly 
assigned to receive gemcitabine with or without cisplatin [3]. Median progression- free and 
overall survival were superior in the combination arm (8.0 versus 5.0 months and 11.7 versus 8.1 
months, respectively; P<0.001), with the benefit seen consistently across the BTC subtypes. For patients  who progress following first -line therapy there is no outright standard second- line option 
and therapy is usually an extr apolation from agents used in pancreatic or other gastrointestinal 
cancers [
4]. Clearly, there is an unmet need here to improve the treatment options at every s tage 
for patients diagnosed with this relatively uncommon cancer type.  
1.2.2 Immune-based approaches in gastrointestinal malignancies  
The past  number of years have seen much progress for immune -based approaches i n solid tumor 
malignancies, with FDA approvals f or various strategies, including dendritic cell vaccination 
(prostate cancer) as well as so -called immune checkpoint inhibition, targeting CTLA4 or the 
PD1/PDL1 axis (melanoma, lung, kidney cancer) [5-7]. These latter therapies in particular have 
generated enormous excitement across the entire field of  oncology, providing r eal and major 
benefit to a significant minority of patients, as well as teaching us a great deal  about the immune 
system in our efforts to predict who will benefit from treatment. Appreciation of the role of immune -evasion in developing tumors was evidenced by its inclusion as one of the (updated) 
hallmarks of cancer [
8]. The next steps seem to be clear, at least in outl ine, with current atte mpts 
in the clinic focusing on identifying those  patients who will or will not respond to treatment 
while at the same time expanding the proportion of patients in each cancer type who can experience the real and dramatic benefits seen  with immune -based app roaches. The next frontier 
is for these treatmen ts to prove themselves, even in principle, in di seases which have thus far 
proved relatively refractory. So far, with some notable exceptions, this has unfortunately included cancers of the gastrointestinal tract, including BTC. One of the first studies evaluating and showing impressive results of PD1/P DL1-directed therapy was disappointing from a GI 
cancer viewpoint [
9]. There were no responses in any of cohorts cont aining patients with 
colorectal (N=18), pancreatic (N=14) and gastric (N=7) cancer. Similarly , negative results for GI 
cancers were seen both in other studies of anti -PD1 therapy and also CTLA4 inhibition[ 10-12 ]. 
The notable exceptions to this disappointing, preliminary experience, have been in mismatch 
repair -deficient colorectal cancer – where exceptional responses to PD -1 inhibition have been 
seen – and also hepatocellular carcinoma [13, 14]. The former situation results in a marked 
increase in the non- synonymous mutagenic burden within tumors, thereby – presumab ly – 
increasing the likelihood that a tumor -specific neoantigen is generated which is recognized by 
the immune system[ 15]. This of course is relevant for any tumor type which happens to have a 
high mutagenic burden, either because of inherited or acquire d mismatch repair deficiency - 
resulting in a de gree of microsatellite instability (MSI -hi) – or other factors. In the study by Le et 
al. MSI -hi non- colorectal cancers also responded excellently well and in melanoma and non -
small cell lung cancer mutagenic  burden has been associated with benefit to immune checkpoint 
inhibition [16, 17]. The findings of activity of anti -PD1 therapy in HCC are particularly apt for  
cholangiocarcinoma however, given their overlapping etiology and the common basis of both 
tumor types in inflammation. In BTC itself, eme rging data suggests cl inical activity with 
immune checkpoint inhibitio n in the clinic and, though very preliminary, is  encouraging, 
particularly in the context of the underlying rationale for why this should be the case[ 18, 19 ].  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
10 1.2.3 Inflammation and predisposition to biliary tract carcinoma.  
The causative link and similarity between inflammation and cancer de velopment stretches ba ck 
to the 19th century observations of Rudolph Virchow and, indeed, even two millennia earlier t han 
that to the time of the first physicians [20]. Chronic inflammation can greatly facilitate cance r 
development and progression through a number of me ans, culminating in the development of an 
immunosuppressed microenvironment, whereby host anti -tumor immunity is evaded or 
inhibited [21]. This broad and sometimes paradoxical relationship between cancer and 
inflammation is particularly relevant in BTC, a can cer – like HCC, the other, more prevalent 
primar y liver cancer – whose main associated predispos ing conditions have chronic 
inflammation as their common underlying pathological denominator. Although the majority of 
patients with BTC will have no identifiab le cause on an individual basis, strong associat ions 
exist between BTC and various disparate inf lammatory conditions[ 22]. The dominant known risk 
factor for gallbladder carcinoma is cholelithiasis -induced chronic inflammation[ 23], whereas – 
worldwide – infestation of the biliary ducts by parasites or persistent hepatolithiasis are 
important predisposing factors for intrahepatic cholangiocarcinoma [24]. In the US and Europe 
prima ry biliary cirrhosis and sclerosing cholangitis are all established ri sk factors for BTC, as are 
causes of intrahepati c in flammation – hepatitis, diabetes, obesity  for example – whose 
importance in the etiology of intrahepatic cholangiocarcinoma is being i ncreasingly 
appreciated[ 25]. Recent studies have linked liver disease associat ed with the increasing incidence 
of chronic hepa titis C virus infection with intrahepatic cholan giocarcinoma[ 26], which may 
explain in part the increasing occurrence of this subtype (intrahepatic type) of biliary tract cancer [
27]. For established cancer the Glasgow prognostic score (GPS), an inflammation- based 
prognostic score, has been shown to predict for postoperative outcome for BTC[ 28]. 
The finding of an immune role in the etiology of BTC is important because it raises the possibility of an immune -based remedy in at least  a proportion of patients. This is not only 
relevant for established cancer but also in the long antecedent period of inflammation and pre -
malignancy where the opportunity for prevention exists. It has been shown that cholangiocytes have the ability to pre sent antigens and can activate a subset of lymph ocytes called Natural Killer 
T (NKT) cells [29
]. Primary sclerosing cholangitis (PSC) and pr imary biliary cirrhosis (PBC) are 
characterized by a marked hepatic mo nonuclear infiltration, but this is also a featu re of other 
chronic liver diseases, including environmentally- driven conditions such as alcoholic 
cirrhosis [30]. As stated above, all of these conditions incre ase the risk of developing BTC[ 31]. In 
PSC,  a mark ed CD4+ and CD8+ T -cell infiltration in portal tract s and around bile ducts is 
seen[32]. Interestingly, it seems that the pattern of antigen- driven clonal expansion of T cells 
may vary according to the underlying predisposing condition, with distinct T -cell receptor (TCR) 
signatures reflective of different antigenic repertoires [30]. This was suggested by Liaskou et al. 
who performed high- throughput sequencing of the TCR  beta chain complementarity -determining 
region 3 of liver -infiltrating T cells in s amples derived from pa tients with primary sclerosing 
cholangitis, primary biliary cirrhosis and alcoholic cirrhosis [30]. These analyses revealed the 
presence o f distinct disease -associated clonotypes which differed by degree. For  example, in 
alcohol- related disease, a pronounc ed o ligoclonal nature of liver infiltrating T cells was 
observed, in contrast to a higher diversity amongst T- cells infiltrating PSC.  
1.2.4 Imm unogenicity of biliary tract carcinoma.  
The success of immune checkpoint inhibition is dependent first and foremost upon t he presence 
of an already existing endogenous anti -tumor immune response, which can then be amplified or 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
11 disinhibited. In the absence of initial immune reco gnition this class of agents won’t be effective,  
as – by definition – there will be no adaptive resi stance or suppression to overcome. Spontaneous 
immune responses do occur in established BTC. This was illustrated in dramatic fashion by 
Rosenberg and colleagues who performed whole -exome- sequencing on the resected tumor of a 
patient with metastatic ch emo-refractory cholangiocarcinoma in order to identify mutations 
which could serve as neo-antigens[ 33]. By generating tandem minigene (TMG) constructs of 
each of th e mu tations and co -culturing with expanded populations of the isolated tumor 
infiltrating lymphocytes (TIL), they were able to identify a clonal population of CD4+ T helper 1 (T(H)1) cells which were reactive to a mutation in erbb2 interacting protein (ERB B2IP ) in the 
tumor. Via adoptive transfer of enriched populations of these cells, cultured ex- vivo, the 
investigators could produce persistent tumor regression. This case confirms that tumor -
associated antigen (TAA) -provoked immune responses do occur in cholan giocarcinoma as well 
as illustrating that, in principle, the exact nature of this response can be isolated by currently available tech nologies, quanti tatively  enhanced, enriched, and then administered back to the 
patient with therapeutic effect[
33]. Beyond the proof of concept however, the wider r elevance of 
this case to cholangiocarcinoma is uncertain. It was notable in this patient that only 26 nonsynonymous mutations were identified in the tumor, a relatively low number in comparison to, for example, UV -associated melanoma or cigarette -induced l ung cancer, where a mu ch 
greater mutagenic burden appears to increase the chances of generating an epitope or epitopes  
capable of inciting a strongly reactive immune response. Cholangiocarcinoma in general is not a 
highly mutated cancer. For example, in 239 cases of BTC in whom  whole -exome sequencing 
was performed the median  numbers of non- silent somatic mutations across the ICC (N=137 
cases), ECC (N=74 cases) and gallbladder cancer (N=28 cases) subtypes were 39, 35 and 64, respectively [
34]. Interestingly, in that analysis, a sma ll proportion (5.9%) of cases were 
identified as having a very high number of mutations (median no. = 641), 5 of whom had defects in the m ismatch -repair apparat us. We have seen already that this population of  MSI-hi tumors 
respond excellently well to anti -PD1 therapy[
35]. Also, of special interest in this analysis was 
that via unsupervised clustering of global gene expression levels, determined by transcriptome sequenci ng, four molecular subgroups of BTC were elucidated which could be divided into 
prognostic categories. The group which had the poorest prognosis demonstrated enrichment for genes involved in the immune system  and cytokine activity. The hypermutated tumors were  part 
of this cluster and expression of immune checkpoint molecules, including PD -L1, was 
significantly higher in this poor outcome group. This suggests that in addition to the pro-tumorigenic effects of inflammation, escape from immunity is achieved b y the tumor – at least in 
a significant proportion of cases – via the upregulation of targetable (and now FDA -approved) 
strategies.  
Perhap s the best indicator o f an already existing, but possibly suppressed, antitumor immunity is 
the presence of immune cel ls which have already migrated to the tumor. Tumor infiltrating 
lymphocytes (TIL) have been shown in a variety of non- GI cancers to be prognostic as well as 
predictive of efficacy in immune and non- immune the rapeutic approaches [36-39 ]. In melanoma, 
the presence of T -cell-infiltration, particularly th ose with high CD8 T -cell content, are more 
likely to be associated with PD -L1 expression in tumor cells – making them more  susceptible to 
anti-PD1/PDL1 treatment – and an improved prognosis [39]. The presence of TIL has likewise 
been shown to be a favorable prognostic factor in a variety of GI cancers such as colorectal 
cancer and pancreatic cancer [40-42 ]. Recent evidence has highlighted the link between overall 
mutagenic burden, immune react ivity and – in the case of UV -associated melanoma, cigarette -
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
12 induced lung and MMR -deficient colon cancer especially – dramatic responses t o immune 
checkpoint inhibition. However, Tran and colleagues have recently suggested that the 
relationship is more nua nced  than that, with the finding – through the same TMG approach 
mentioned above – of immunoreactive TIL even in the setting of low burden  mutational 
burden[ 43]. These investigators found that in patient s with gastrointestina l cancers whose tumors 
had, as expected, a low mutation burden (range 10- 155) T -cell responses again st at least one 
somatic mutation were still present and identifiable in nine out of ten cases.  
In BTC, the prevalence and prognostic relevance of infiltrat ing T -lymphocytes has also been 
documented. Sabbatino et al. evaluated lymphocyte infiltration ( as well as HLA and PDL1 
expression in 27 cases of ICC [44]. All tumor specimens had TIL, and this correlated – as one 
would expect – with HLA expression. Nakakubo et  al. investigated the significance of tumor -
infiltrating immune cells in 110 surgically resected biliary tract cancer (gallbladder) specimens [
45]. They found high levels of CD4+ T cell (51.1%), CD8+ T cell (37.8%), NK cell 
(33.3%), and dendritic cell (48.9%) infiltration. CD4+ and CD8+ T cell i nfiltration correlated  
with decreasing tumor invasion, and high number s of infiltrating DCs correlated with decreasing  
lymph-node tumor metastasis. Furthermore, increased infiltration of CD4+ and CD8+ T cells and DCs exhibited a significant correlation with prolonged survival. In a similar analysis, Goeppert 
et al. evaluated  immune cell infiltration in 375 cases of biliary tr act cancer obtained following 
surgical resection [
46]. Approxi mately half the patients had some degree of intr aepithelial CD8 T 
cell tumor infiltration and th is – in addition to other inflammatory infiltrate – decreased with 
increasing stage of disease. The presence of intraepithelial tumor- infiltrating CD4+ T 
lymphocytes as well as CD8+ T lymphocytes correlated s ignificantly with a longer overall 
survival in B TC p atients. Interestingly, patients who had higher total regulatory T lymphocyte 
counts had a better survival outcome. The prognostic value of Tregs in other GI tumor types, especially colorectal cancer, has  been variable in terms of whether it was a favo rable or adverse 
factor [
47]. In cholangiocarcinoma cell lines it has been shown that down -regulation of FOXP3 
inhibits tumor cell invasion by reducing the  quantity of MMP -9 and  MMP -2 as well as 
immunosuppressive cytokines (I L-10 and TGF -b1) produced by the tumor cells lea ding to better 
T-cell survival, suggesting that FOXP3 plays an important role in the evolution of the malignant 
phenotype[ 48].  
It was also of note in the large sample  analyzed by Goeppert et al that differences were observed 
in the composition of inflammatory infiltrate by anatomical subtype with comparatively less CD8+ infi ltration in intrahepatic disease relative to extrahepatic disease and gallbladder cancer. 
Indeed , the prognostic significance of the presence of intraepithelial T and B lymphocytes 
pertained only to these subtypes and not to intrahepatic cholangiocarcinoma. The potential difference in inflammatory infiltrate according to anatomical subtype noted by G oeppert et al. is 
intriguing, but perhaps not surprising given the differences in molecular derangement or gene expression, different cell  of origin as well as in incidence, risk factors and indeed outcome [49
, 
50]. Although clinically the anatomic al subtypes are treated the same (surgical resection if 
technically fe asible, gemcitabine -based chemotherapy, radiation) t his paradigm has evolved 
more through expediency and clinical trial design or enrollment issues rather than being driven by biological  considerations. As we  move into the immunotherapeutic era we will nee d to pay 
more attention to this, perhaps by stra tification measures to ensure that enough patients in each 
subtype are treated.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
13 Given that antigen- specific adaptive responses are brokered by MHC class 1- presentation of 
tumor peptide to T cells, it has been reported by many investigators across many dise ase types 
that one method of immune evasion is achieved by virtue of changes in expression or 
downregulation of MHC I [51-53 ]. Indeed, downregulation of MHC I expr ession is more 
frequently observed in advanced disease stages and tumors which are poorly differentiated [54, 
55]. 
Goeppert et al. analyzed  the impact of the expression of MHC I on patient survival in BTC as 
well as the quanti tative  and qualitative rel ationship of this factor to tumor- infiltrating immune 
cell types [56]. They evaluated a large cohort of patients (N=334), including extrahepatic (n=129) 
and intr ahepatic cholangiocarcinomas (n=146), as well as adenocarcinomas of the gallbladder 
(n=59). In addition, 71 high-grade bil iary intraepithelial lesions (BilIN 3) were included.  MHC I 
expression was assessed semi -quantitatively and broadly divided into two groups of high and 
low expression patterns, roughly half in half (47.6%  Vs 52.4%).There was a trend for higher 
MHC I ex pression in lower Union for International Cancer Control (UICC) stages (P=0.074) and 
in particular biliary intraepithelial neoplasia (BilI N) 3, where significan tly higher MHC I 
expression levels were seen com pared to invasive tumor s (P=0.004) in addition t o a significant 
association between high MHC I expression and low tumor grade. There was also an association 
between MHC I expression and the number of tumor- infiltrating immune cells. Interestingly, the 
investigators found that the associations differed b y anatomical subtype. The association between 
inflammatory infiltrate and MHC I expression for the whole cohort pertained to ECC, whereas in ICC, MHC I expressi on was correlated significantly only with the number of tumor- infiltrating 
CD8+ T cells. In GBAC , the smallest cohort, a significant correlation of MHC I expression was 
only seen for CD68+ macrophages. Higher MHC I expression on tumor cells was also 
signif icantly associated with longer overall survival with patients exhibiting strong MHC I 
expression having an improved median overall survival of 28 months (versus 20 months for low 
expression; P=0.006). Looking at the subtypes the investigators found in thei r analysis that the 
prognostic significance of MHC I expression on tumor cells, although not rea ching statistical 
significance, was by trend stronger in ECC and GBAC compared with ICC, again suggesting that mechanisms of immune escape may vary with anatomical subtype.  
PD-L1 expression in tumors, induced by interferon- gamma, has been shown to predict  for 
response to PD1-inhibtion[ 57]. The relati onship is not absolute  and additional factors exist in the 
tumor micro environment which contribute to the immunosuppre ssion and dictate the manner of 
response. Nevertheless, PDL1 expression is likely to be the first companion diagnostic to make it into clinical practice as a pr edictive test of benefit to checkpoint inhibition. In BTC Ye et al. 
evaluated the expression of B7 -H1 (PD -L1) and its ligand PD -1 in N=31 surgically resected 
cases in addition to the corresponding cancer adjacent tissues [
58]. Expression of PD -L1 and PD -
1 was found to be up -regulated in cholangiocarcinoma tissues compared with the cancer adjacent 
tissues. Tumor -related PD -L1 expression was significa ntly correlated with b oth tumor 
differentiation and pTNM stage and was  inversely correlated with CD8+ tumor -infiltrating 
lymphocytes. In the analysis by Sabbatino et al. 8 of 27 ICC cases expressed PD- L1[44].  
1.2.5 Translational immune -based efforts  in BTC  
There is a paucity of rand omiz ed clinical trials for BTC, no doubt because of the relative rarity of 
this tumor type. In addition, the cholangiocarcinoma -specific p hase 2 studies which a re available 
to patients tend towards the evaluation of chemotherapeutic combinations ( e.g. FOLF IRIN OX or 
gemcitabine  + nab -Paclitaxel) which have already shown efficacy in other indications, and the 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
14 usefulness of which investigators are attempting to asse rt in BTC. As a result of this, progress in 
BTC has seemed to lag behind that of other, more com mon solid tumors, with a dearth of studies 
evaluating new and innovative drugs. Traditionally, BTC patients could for the most part only 
access clinical trials in the phase 1 setting. With the advent of immune- based approaches, this 
paradigm shows signs of  change, with less emphasis on the initial dose -escalation phase of drug 
development - important mainly for dose limiting toxicity (DLT) determination in the ev aluation 
of cytotoxic agents - in favor of large , basket studies allowing multi -histology cohorts, s uch as 
the initial anti- PD1 studies [59, 60], in which pure DLT -determination in the first 28days is le ss 
crucial. Table 2 shows the currently open and accruing studies employing an immune -based 
approach currently available on clinicaltrials .gov and which are spe cific to BTC or have BTC 
explicitly stated as an  eligible histology.  
In terms of published or presented clinical data for immune approaches in BTC the experience in the literature is dominated by peptide vaccines, most commonly directed against mucin protein 1 (MUC1) or Wilm’s Tumor protein 1 (WT1) [61
]. These small studies have be en w ell tolerated 
without showing a strong clinical signal of efficacy[ 62, 63]. For example, Aruga and colleag ues 
conducted a small phase I clinical trial evaluating multiple -peptide vaccination for patients with 
advanced BTC [64]. The vaccine selected comprised three cancer -testis antigens that were 
identified using cDNA microarray technology coupled with laser microdissection and which were found to be overexpressed in nearly 100% of BTC. Patients were vaccinated on a continuous basis even if their disease had progressed. P eptide-specific T cell immune responses 
were observed in all patients and stable disease, prolonged in a couple of cases and associated with increased CXCR3+CCR 4- T cells, was observed in 5 of 9 patients. The  median PFS and OS 
of 3.4 and 9.7 months respect ively. The same investigators had earlier tested a different four -
peptide vaccine, similarly well tolerated observing peptide -specific T -cell immune responses i n 
seven of nine patients and clinical responses – including two instances of minor response not 
reaching PR criteria - observed in six of nine patients [
65]. Dendrit ic-cell based vaccines have 
also been evaluated,  most commonly in combination with standard moda lities, such as surgical 
resection and/or chemoradiation, and which complicates assessment of efficacy [66, 67 ].  
The published or presented experience with immune checkpoint inhibitors is very preliminary. Documented response to anti -CTLA4 ther apy (with tremelimumab ) has been seen, interestingly 
manifesting as a delayed response after initial progression of di sease[18
]. The early data for anti -
PD1 inhibit ion (pembrolizumab) has been recently presented, showing encouraging evidence of 
efficacy (17% partial response rate) in BTC, and which seems broadly in line with use of this agent in other solid tumor studies where no pre -selection based on PD -L1 expr ession or MSI 
status was performed [
19].  
One of the great advantages and promises of immune -based  approaches is the potential role for 
their combination with standard therapies, either cytotoxic agents which have immune -
modulatory effects or strategies such as radiation or interventional radiologic procedures, in 
whom participation of the immune s ystem has been shown to be a determinant in how they 
work [68]. Certa in chemotherapeutics can activate rather than su ppress the immune system and 
that a robust immun e response is a necessary component determining tumor response [69]. 
Gemcitabine is a nucleoside analogue that is part of the standard treatment, and probably the most common chemotherapeutic agent used in BTC [
3, 70]. The im mune effects of gemcitabine 
have been studied pe rhaps more than for any other drug used in GI cancer. Its effects on the 
immune system are diverse [68]. With regard to BTC Koido et al. demonstrated that in ICC cel ls 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
15 isolated from a patient with malignant ascites immunogenic modulation of the cells could be 
induced by gemcitabine with upregulation of  MHC class I and II, c alreticulin – a modulator or 
immunogenic cell de ath – MUC1 and WT1 mRNA [71]. Interestingly, the authors found that 
gemcitabine also induced up- regulation of immunosuppressive PDL1, suggesting a potential 
rationa le for combination therapy. Ablative therapies are o ccasionally employed in the 
management of BTC, although with a much smaller role than in HCC for example. Following 
RFA, tumor antigens from necrotic tumor are taken up by antigen -presenting cells (mainly  DCs), 
activating tumor -specific immune response s[72, 73]. Ablated tumor tissue promotes DC 
maturation [74, 75]. A tumor -specific immune respons e may prevent recurren t disease in addition 
to treating distant metastases. Several preclinical and clinical studies h ave documented an 
increase in peripheral immunity following ablation[ 74, 76-79 ]. We are currently conducting a 
study evaluating subtotal RFA in combination with anti -CTLA4 therapy ([STUDY_ID_REMOVED]) in 
patients with HCC and BTC. Provisionally, this a pproach is feasible and safe, with some early 
evidence of efficacy, wh ich needs to be confirmed with more patient numbers and more mature 
follow-up[ 80].  
1.2.6 Pembrolizumab  
Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the inte raction between PD -
1 and its ligands, programmed cell death ligand 1 (PD -L1) and programmed cell death ligand 2 
(PD-L2). This blockade  enhances functional a ctivity of the target lymphocytes to facilitate tumor 
regression and ultimately immune rejection . 
On 04- Sep-2014, the United States (U.S.) Food and Drug Administration (FDA) granted  
accelerated approval to KEYTRUDA
® for treatment of subjects with unresectable or  metastatic 
melanoma and disease progressi on following treatment with ipilimumab (IPI) and , if BRAF 
V600 mutation positive, a BRAF inhibitor. The recommended dose of  KEYTRUDA is 2 mg/kg 
administered as an intravenous (IV) infusion over 30 minutes eve ry 3 weeks (Q3W) until disease 
progression or unacceptable toxicity. This indication was  approve d based on tumor response rate 
and durability of response (data cutoff date  18-Oct-2013) observed in a total of 411 IPI -
refractory plus IP I-naïve melanoma subjects  enrolled in P001 and treated with 1 of 3 dos e 
regimens of pembrolizumab (2 mg/kg Q3W, 10 mg/kg Q3W, or 10 mg/kg every 2 weeks 
[Q2W]). An improvement in survival or  disease -related symptoms had not yet been established 
at the time of the FDA filing. 
On October 24, 2016, the U.S. Food and Drug Administration approved pembrolizumab 
(KEYTRUDA, Merck & Co., Inc.) for the treatment of patients with metastatic non -small cell 
lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA -approved test. 
This was the first FDA approval of a checkpoint inhibitor for first -line treatment of lung cance r. 
This approval also expanded  the indication in second- line treatment of lung cancer to include all 
patients with PD -L1-expressing NSCLC. 
The FDA approval added the following indications for pembrolizumab: 
• Patients with metastatic NSCLC whose tumors have high PD-L1 expression (Tumor 
Proportion Score [TPS] greater than or equal to 50%) as determined by an FDA-approved 
test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treat ment for metastatic NSCLC.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
16 • Patients with metasta tic NSCLC whose tumors express PD -L1 (TPS greater than or equal 
to 1%) as determined by an FDA -approved test, with disease progression on or after 
platinum-cont aining chemotherapy. Patients with EGFR or ALK genomic tumor 
aberrations should have disease progres sion on FDA -approved therapy for these 
aberrations prior to receiving pembrolizumab. 
Approval was based on results of two randomized, controlled trials that demonstrated 
statistically significant improvements in progression- free survival (PFS) and over all survival 
(OS) for patients randomized to pembrolizumab compared with chemotherapy. 
In a trial of 305 patients who had no prior treatme nt for metastatic NSCL C and TPS greater than 
or equal to 50%, those who received pembrolizumab (200 mg every 3 weeks) had a significant 
improvement in PFS (HR 0.50 [95% CI: 0.37, 0.68]; p<0.001) with a median PFS of 10.3 
months versus 6.0 months for those receiving platinum -based chemotherapy. A pre -specified 
interim analysis demonstrated a statistically significant impro vement in OS for patients 
randomized to pembrolizumab as compared with chemotherapy (HR 0.60 [95% CI: 0.41, 0.89]; p<0.005).  
In a three -arm trial of 1033 patients who were previously treated for metastatic NS CLC with a 
TPS greater than or equal to 1%, thos e randomized to pembrolizumab 2 mg/kg every 3 weeks 
(HR 0.71 (95% CI: 0.58, 0.88]; p<0.001) or pembrolizumab 10 mg/kg every 3 weeks (HR 0.61 [95% CI: 0.49, 0.75 ]; p<0.001) had an improved OS compared with pat ients receiving docetaxel. 
The median survival w as 10.4 months in the pembrolizumab 2 mg/kg arm, 12.7 months in the 
pembrolizumab 10 mg/kg arm, and 8.5 months in the docetaxel arm. 
The r ecommended dose and schedule of pembrolizumab for NSCLC is 200 mg intr avenously 
every three weeks.  
1.2.6.1 Nonclinical Pharmacology 
Pembrolizumab binds to human and Cynomolgus monkey PD -1 with comparable affinity and 
blocks the binding of human and Cynomolgus monkey PD -1 to PD -L1 and P D-L2 with  
comparable potency. Pembrolizumab does not cross-react with dog, rat, or mouse PD-1. 
Pembr olizumab does not bind immunoglobulin superfamily members cluster of  differentiation 
28 (CD28), cytotoxic T -lymphocyte- associated prot ein 4 (CTLA -4), or  inducible T -cell co -
stimulator (ICOS).  
Pembrolizuma b strongly enhances T -lymphocyte immune response s in cultured blood cells  from 
healthy human donors, cancer subjects, and nonhuman primates. In T- cell activation  assays using 
human donor  blood cells, the half -maximal effective concentration (EC
50) has  been 
approximately 0.1 to 0.3 nM. In addition to int erleukin- 2 (IL -2), tumor necrosis factor  alpha 
(TNFα), interferon gamma (IFN ɣ), and levels of other cytokines were found to be modulated by 
pembrolizumab. The antibody potentiates existing immune responses only in the presence of 
antigen and does not nonspecifically activate T -cells. In the in vitro peripheral blood 
mononuclear cell (PBMC) and whole blood cytokine release assays, the  cytokine levels induced 
by pembrolizumab were low and comparable to those induced by trastuzumab. Pembrolizumab 
does not induce antibody- dependent cell -mediated cytotoxicity  (ADCC) or complement -
dependent cytotoxicity (CDC). 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
17 Using anti –murine PD -1 surrogate antibodies, PD -1 blockade has been shown to significantly  
inhibit tumor growth in a variety of syngeneic murine tumor models. In these experiments in 
mice, anti –PD-1 therapy is synergistic with chemotherapeutic agents such as gemcitabine and  5-
fluorouracil (5 -FU), and combination therapy results in increased complete tumor  regression 
rates in vivo. Studies also revealed that immunosuppressive doses of  dexamethasone included in  
combination with agents used in standard- of-care treatment for  NSCLC do not reduce the anti -
tumor efficacy of an anti –murine PD-1 surrogate antibody. 
1.2.7 Rationale for Dose Selection/Regimen/Modification  
An open- label Phase I trial (Protocol 001) was  conduct ed to evaluate the safety and clinical 
activity of single agent pembrolizumab . The dose escalation portion of  this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks (Q2W) in subjects with advanced solid tumors. A ll three dose levels were well tolerated,  and no dose -limiting 
toxicities were observed.  This first in human study of pembrolizumab showed evidence of target 
engagement and objective evidence of tumor size reduction at all dose levels (1 mg/kg, 3 mg/kg 
and 10 mg/kg Q2W). No MTD was  identified.  Recent data from other clinical studies within the 
pembrolizumab progr am has shown that a lower dose of pembrolizumab  and a less frequent 
schedule may be sufficient for target engagement and clinical activity.  
PK data analysis of pembrolizumab administered Q2W and Q3W showed slow systemic 
clearance, limited volume of distrib ution, and a long half -life. Pharmacodynamic data (IL -2 
release assay) suggested that peripheral  target engagement is durable (>21 days). This earl y PK 
and pharmacodynamic data provides scientific rationale for testing a Q2W and Q3W dosing schedule.   
A population pharmacokinetic analysis was  performed using serum concentration time data from 
476 patients. Within the resulting population PK model, cle arance and volume parameters of 
pembrolizumab were found to be dependent on body weight. The relationship bet ween clearance 
and body weight, with an allometric exponent of 0.59, was within the range observed for other 
antibodies and would support both body weight normalized dosing or a fixed dose across all 
body weights. Pembrolizumab  has been found to have a wide therapeutic range based on the 
melanoma indication.  The differences in exposure for a 200 mg f ixed dose regimen relative to a 
2 mg/kg Q3W body weight- based  regimen are anticipated to remain well within the established 
exposure margins of 0.5 – 5.0 for pe mbrolizumab  in the melanoma indication. The exposure 
margins are based on the notion of similar efficacy and safety in melanoma at 10 mg/kg Q3W vs. the proposed dose regimen of 2 mg/kg Q3W (i.e. 5- fold higher dose and exposure). The 
population PK evaluation revealed that there was no significant impact of tumor burden on exposure. In addition, exposure was similar between the NSCLC and melanoma indications. Therefore, there are no anticipated changes in exposure between different indication settings. 
The rationale for further exploration of 2 mg/kg and comparable doses of pembrolizumab in 
solid tumors  is based on: 1) similar efficacy and safety of pem brolizumab when dosed at either 2 
mg/kg or 10 mg/kg Q3W in melanoma patients, 2) the flat exposure -response relationships of 
pembrolizumab for both efficacy and safety in the dose ranges of 2 mg/kg Q3W to 10 mg/kg Q3W, 3) the lack of effect of tumor burden  or indication on distribution behavior of 
pembrolizumab (as assessed by the population PK model) and 4) the assumption that the dynamics of pembrolizumab target engagement will not vary meaningfully with tumor type. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
18 The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on 
simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual pa tients exposure in the exposure range established i n melanoma that 
are well tolerated and safe.  
A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and 
to reduce potential for dosing errors.  A fixed dosing scheme will also reduce complexity in the 
logistical chain at treatment facilities and reduce wastage.  
1.2.8 CAPOX in biliary tract carcinomas  
For metastatic or unresectable disease the modest standard of care for BTC comprises gemcitabine in combination with cisplatin ch emotherapy, based on the ABC -02 trial in which a 
total of 410 patients with unresectable locally advanced or metastatic disease were randomly 
assigned to receiv e gemcitabine with or without cisplatin [3
]. Median pr ogression- free and 
overall survival were superior in the combination arm (8.0 versus 5.0 months and 11.7 versus 8.1 months, respectively; P<0.001), with the benefit seen consistently across the BTC subtype s. For 
patients who progress following first -line therapy there is no outright standard second- line option 
and therapy is usually an extrapolation from agents used in pancreatic or other gastrointestinal cancers [
4]. The choice in this study of CAPOX as an acceptable chemotherapy component is an 
extrapolation of the wide use of oxaliplatin/5FU -based combinations in all GI cancers. The use 
of capecitabine (as opposed to infusional 5- FU) has the added convenience of not requiring 
continuous IV infusion. 
2 ELIGBILITY ASSESSMEN T AND ENROLLMENT  
2.1 ELIGIBILITY CRITERIA  
2.1.1 Inclusion Crite ria 
2.1.1.1 Patients must have histopathological confirmation of biliary tract carcinoma (BTC) by the Laboratory of Pathology of the NCI prior to entering this study OR 
histopathological confirmation of carcinoma in the setting of clinical and radiological  
charact eristics which, together with the pathology, are highly suggestive of a diagnosis 
of biliary tra ct carcinoma. The  term BTC includes intra - or extra hepatic 
cholangiocarcinoma, gallbladder cancer or ampullary cancer. 
2.1.1.2 Patients must have disease that is not amenable to potentially curative resection . 
Patients must have received , been intolerant of or ref used at least one line of 
chemotherapy .  
2.1.1.3 Patients must have at least one focus of measurable metastatic disease  per RECIST 1.1. 
(Section 6.3). 
2.1.1.4 Patients must have at least one focus of metastatic disease that is amenable to pre- and 
on-treatment biops ies. Ideally  the biopsied lesion should not be one of the target 
measurable lesions, although this can be up to the discretion of the investigators. 
2.1.1.5 Age >18 years  
2.1.1.6 ECOG performance status 0 -1 (see Appendix A ) 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
19 2.1.1.7 Patients must hav e normal organ and marrow function as defined below: 
leukocytes  >3,000/mcL  
absolute neutrophil count  > 1,000 /mcL  
platelets  ≥ 100,000/mcL  
total bilirubin  ≤ 2 xULN  
Serum albumin  ≥ 2.5g/dl  
Patients are eligible with ALT or AST up to  5 x ULN.  
creatinine  <1.5X institution upper limit of 
normal 
OR 
creatinine clearance  >45 mL/min/1.73 m2 for patients with 
creati nine levels abov e institutional 
normal  
2.1.1.8 Patients must have recovered from any acute toxicity related to prior therapy, including 
surgery. Toxicity should be ≤  grade 1 or returned to baseline. 
2.1.1.9 Patients must not have other invasive malignancies within the pa st 5 years (with  the 
exception of non- melanoma skin cancers , non- invasive bladder cancer  or localized 
prostate cancer for whom systemic therapy is not required).  
2.1.1.10 Patient must be able to understand and willing to sign a written informed consent document. 
2.1.1.11 The effects of Pem brolizumab in combination with Capecitabine and Oxaliplatin on the 
developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and up to 120 days after the last dose of the drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.  
2.1.2 Exclusion Criteria  
2.1.2.1 Patients who have had standard of care chemotherapy, large field radiotherapy, or major surgery must wait 2 weeks prior to entering the study. 
2.1.2.2 Previous treatment with immune checkpoint inhibitors.  
2.1.2.3 Patients who have undergone prior liver transplantation are ineligible. 
2.1.2.4 Patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. 
2.1.2.5 Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhyt hmia  (excluding insignificant sinus bradycardia and sinus tachycardia)  or 
psychiatric illness/social situations that would limit compliance with study requirements . 
2.1.2.6 History of (non -infectious) pneumonitis that required steroids, evidence of interstitial 
lung disease or active, non-infectious pneumonitis. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
20 2.1.2.7 History of chronic autoimmune disease ( e.g., Addison’s disease, multiple sclerosis, 
Graves’ disease, Hashimoto’s thyroiditis, rheumatoid arthritis, hypophysitis, etc.) with 
symptomatic disease within the 3 years before ran domization. Note: Active vitiligo or a 
history of vitiligo will not be a basis for exclusion.  
2.1.2.8 Dementia or significantly altered mental status that would prohibit the  understanding or 
rendering of Information and Consent and compliance with the requirement s of the 
protocol  
2.1.2.9 Active or history of inflammatory bowel disease (colitis, Crohn’s), irritable bowel  
disease, celiac disease, or other serious, chronic, gastrointestinal conditions  associated 
with diarrhea. Active or history of systemic lupus erythematosus or  Wegener’s 
granulomatosis. 
2.1.2.10 Currently receiving immunosuppressive doses of steroids or other  immunosuppressive 
medications (inhaled and topical steroids are permitted)  
2.1.2.11 History of sarcoidosis syndrome. 
2.1.2.12 Known history of active tuberculosis. 
2.1.2.13 Patients should not be vaccinated with liv e attenuated vaccines within 1 month of 
starting pembrolizumab treatment.  
2.1.2.14 Active  hepatitis B or C infection.  
2.1.2.15 HIV-positive patients receiving anti -retroviral therapy are excluded from this study due 
to the possibility of pharmacokinetic interactions between antiretroviral medications and pembrolizumab. HIV positive patients not receiving antiretroviral therapy are excluded due to the possibility that pembrolizumab may worsen their condition and the 
likelihood that the underlying condition may obscure the attribution of adverse events. 
2.1.2.16 History of hypersensitivity reaction to human or mouse antibody products. 
2.1.2.17 Female patients who are pregnant or breastfeeding. Because there is an unknown but potential risk for adverse  events in nursing infants secondary to treatment of the mother 
with Pembrolizumab  in c ombination with Capecitabine and Oxaliplatin , breastfeeding 
should be discontinued.  
2.1.2.18 Patients with unhealed surgical wounds for more than 30 days.  
2.1.2.19 Prior therapy with oxaliplatin  
2.1.3 Recrui tment Strategies  
The study may be abstracted into a plain language announcement  posted on NIH websites, 
including www. clinicaltrials.gov and the CCR website,  and on NIH social media platforms. 
Outside providers and coll eagues may directly refer patients fo r screening into this study. 
2.2 S
CREENING EVALUATION  
Studies should be done within 28 days prior to enrollment unless otherwise noted below. 
Note:   Screening evaluation  testing/procedures are conducted under the separate screening  
protocol, 01-C- 0129 ( Eligibi lity Screening and Tissue Procurement for the NIH Intramural 
Research Program Clinical Protocols ). 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
21 • Complete  medical  history (including prior hormone use) and physical examination (i ncluding 
height, weight, vital signs, EKG, and ECOG performance status ). 
• Laboratory Evaluation 
o Hematological profile: CBC with differential and platelet count.  
o Biochemical profile: electrolytes, BUN, creatinine, AST,  ALT, total and direct 
bilirubin, calcium, phosphorus, albumin, magnesium,  
o Serum or urine pregnancy test for female participants of childbearing age (in the 
absence of prior hysterectomy).  
o HIV, Hepatitis B and C serology and/or viral load  
o TB testing (if  clinically indicated)  
• CT or PET of chest, abdomen and pelvis (or MRI abdomen) 
• Histologic confirmation (at any time point prior to enrollment). A block or unstained slides 
of primary or metastatic tumor tissue will be required from each participant to conf irm 
diagnosis with analysis being performed by the Laboratory of Pathology, NIH . If there is no 
available tumor sa mple, biopsy will be performed to confirm the diagnosis.  
2.3 REGISTRATION PROCEDURES  
Authorized staff must register an eligible candidate with NC I Central Regist ration Office (CRO) 
within 24 hours of signing consent. A registration Eligibility Checklist from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be compl eted and  sent via 
encry pted email to: NCI Central Registration Office  ncicentralregistration -l@mail.nih.gov . After 
confirmation of eligibility at Central Registration Office, CRO staff will call pharmacy to advise 
them  of the acceptance of the patient on the protocol prior to the release of any investigational 
agents . Verification of Registration will be forwarded electronically via e -mail to the research 
team. A recorder is available during non-working hours. 
2.3.1 Treatment  Assignment Procedures (For registration purposes only): 
Cohorts 
Number  Nam e Description  
1 1 Subjects with advanced biliary tract carcinoma  
Arms  
Number  Name  Description  
1 1 Pembrolizumab  + Oxaliplatin  + Capecitabin e 
Arm assignmen t 
Subjects in Cohort 1 will be directly assigned to Arm 1. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
22 2.4 BASELINE EVALUATION  
Tests done at  screening do not need to be repeated on baseline if performed in designated time 
frame . 
Within 28 days prior to first dose: 
• CT or PET of chest, abdomen and pelvis (or MRI abdomen)  
• Elect rocardiogram  
• HLA phenotype (any time prior to first dose) 
• Optional tumor biopsy for research  
Within 7 days prior to first dose: 
• History and physical exam with vital signs  
Within 72 hours prior to first dose: 
• Serum o r urine pregnanc y test for female parti cipants of childbearing age (in the 
absence of prior hysterectomy).  
3 STUDY IMPLEMENTATION  
3.1 STUDY DESIGN  
The proposed study is a phase II study of Pembrolizumab in combination with CAPOX in 
patients with advanced biliar y tract carcinoma.  
 
Group  N PEMBROLIZUM AB CapOx  
Previously 
treated BTC  19 Day 1: Pembrolizumab 
200mg IV, 30 minut es. 
q-3-weekly  until PD  Day 1: Oxaliplatin 130mg/m2 IV 
over 2 hours  
Days 1 –14: Capecitabine 750 mg/m2 
twice daily PO.  
q-3-weekly  for 18 week s 
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
23  
 
 
3.2 SCHEDULE  
Pembrolizumab  and Oxaliplatin should be administered  on Day 1 of c ycles 1-6. Pembrolizumab  
should be infused first and Oxaliplatin should be given at least 30 minutes after Pembrolizumab . 
Capecitabine should be administered orally with first dose the evening of D ay 1 of cycles 1 -6 
and last dose the morning of day 14 of cycles 1 -6, given as intermittent treatment.  
Cycle length is 3 weeks ( consisting of 2 weeks of capecitabine treatment followed by 1 week 
without capecitabine tr eatment ).  
Starting in cycle 7, Pembrolizumab  should be administered alone on Day 1, continuing once 
every 3 weeks until disease progression.  Each cycle may start  up to 3 days before or after the scheduled Day 1 due to administrativ e 
reasons.  
3.3 D
RUG ADMINISTRATION  
3.3.1 Pembroliz umab  
Pembrolizumab 200 mg will be administered as a 30- minute IV infusion on Day 1 of each cycle . 
Every effort  should be made to target infusion timing to be as close to 30 minutes as possible. 
Howev er, a window of - 5 minutes and +10 minu tes is permitted (i.e., infusion time is 25 – 40 
mins ). Please see section  11.1.2 for preparation instructions. 
3.3.2 CAPOX  
Capecitabine should be administered at a dose of 750 mg/m2 PO every 12 hours ( +/- 4 hours 
window is allowed) (equivalent to a total daily dose of 1500 mg/m2) . Doses wi ll be rounded 
downward to the nearest 150 mg. Patients will begin Capecitabine dosing on the first day of 
cycles 1 -6 and will continue to rece ive Capecitabine for 14 days . Patients will be instructed to 
take Capecitabine with food.  No morning dose should be taken on day 1 of the cycle and no D1  
CAPOX  
Screen  
CT Scan  
q9W 
BIOPSY 1  Stop CAPOX  
Continue Pemb q21d  
until PD  
Immune - 
monitoring  BIOPSY 2  D22  
CAPOX  D43  
CAPOX  D64 
CAPOX  D85  
CAPOX  D106  
CAPOX  
Pemb  Pemb  Pemb  Pemb  Pemb  Pemb 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
24 evening dose should be taken on day 14 of the cycle. Pa tents will complete and return Patient’s 
Diary  (Appendix C ). 
Oxaliplatin  should be administered on D1 of cycle s 1-6 at a d ose of 130mg/m² IV Infusion  in 
500mls Glucose 5% over 2 hours. Please see section 11.2.3 for prep aration instruct ions. 
Premedication with ondansetron 8mg and dexamethasone 8mg will be given 15-30 mins prior to 
infusion. 
3.4 DOSING DELAYS AND MODIFICATIONS  
3.4.1 General guidance 
If, in the opinion of the investigator, a toxicity is considered to be due solely to  one drug (e.g. 
hand- foot syndrome secondary to capecitabine, neurotoxicity due to oxaliplatin), the dose of the 
other drug does not require modification.  When, at the beginning of a treatment cycle, treatment delay related to either oxaliplatin or 
capeci tabine treatment  alone is indicated, both oxaliplatin and capecitabine treatment should be 
delayed (except in the case of oxaliplatin -related neurological adverse events). Treatment should 
only be restarted when the requirements for restarting both oxalipl atin and capecitabine are met, 
or when oxaliplatin has to be discontinued but the requirements for restarting cape citabine alone 
are met.  
Dose modifications for isolated abnormal hematologic lab values will be based on hematological parameters at start of  a treatment cycle. There is no scheduled sampling during a treatment cycle 
and thus, no scheduled collection of nadir values.  
If capecitabine must be discontinued permanently due to toxicity, the patient  may continue on 
oxaliplatin alone . If the patient has SD or better  on study, and both capecitabine and oxaliplatin 
are stopped prematurely for toxicity, the PI may consider continuing pembrolizumab. 
3.4.2 Dose Modifications for Hematologic Toxicity 
Capecitabine is not expected to worsen or unduly prolong episodes of 
neutropeni a/granulocytopenia. The  next treatment cycle can only start if hematologic toxicity has 
recovered to grade ≤ 1. No dose reductions or interruptions will be required for anemia (non-
hemolytic) as it can be satisfactorily managed by transfusions. 
3.4.3 Dose Modifications for Neutropenia for Capecitabine and Oxaliplatin 
 
 Grade 2  
1.0 ≤ ANC < 1.5 x 109/L  
Platel ets > 50 - < 75 x 109/L  Grade 3  
0.5 ≤ ANC < 1.0 x 109/L  
Platelets > 10 - < 50 x 109/L  Grade 4  
ANC < 0.5 x 109/L  
Platelets < 10 x 109/L  
1st 
occurrence  No d ose adjustment  Capecit abine 75% of original 
dose + oxaliplatin 100 mg/m2  Capecitabine 50% of 
original dose + 
oxaliplatin 85 mg/m2  
2nd 
occurrence  No dose adjustment  Capecitabine 75% of original 
dose + oxaliplatin 85 mg/m2  Stop treatme nt 
permanently  
3rd 
occurrence  No dos e adjustment  Stop treatment permanently 
unless it is in the best interest 
of the patient to treat with Not applicable  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
25  Grade 2  
1.0 ≤ ANC < 1.5 x 109/L  
Platel ets > 50 - < 75 x 109/L  Grade 3  
0.5 ≤ ANC < 1.0 x 109/L  
Platelets > 10 - < 50 x 109/L  Grade 4  
ANC < 0.5 x 109/L  
Platelets < 10 x 109/L  
capecitabine monotherapy at 
75% of original dose  
3.4.4 Capecitabine  
Given that capecitabine is an FDA -approved agent, dose adjustments and m anagement will be as 
per standard of care, as outlined in the package inser t. Capecitabine will be withheld in cases of 
Grade 2 or greater hand -foot syndrome or mucositis that do not respond to medical management. 
Capecitabine will b e restarted after the s ymptoms improved to Grade 1. The dose of 
Capecitabine may be adjusted in the event of recurrent Grade 2 or greater hand -foot syndrome, 
neutropenia, or other Capecitabine toxicities that have not been attributed to other study agents. 
Summary of management of common Capecitabine toxicities  
Toxicity  Capecitabine dose modification  
Grade 2 hand foot syndrome  Interrupt until ≤ grade 1. May then restart capecitabine at 
full dose. For second occurrence, hold capecitabin e until ≤ 
grade 1, then restart capecit abine one dose level lower 
(75% of starting dose first occurrence, 50% of t he starting 
dose the second occurrence, discontinue the third 
occurrence).  
Grade 3 hand foot syndrome  Interrupt until ≤ grade 1. Then resta rt capecitabine one 
dose level lower (7 5% of starting dose first occurrence, 
50% of the starting dose the second occurrence, 
discontinue the third occurrence).  
*Dose reductions for capecitabine  
1. Starting dose  
2. 75% of the starting dose  3. 50% of the starting dose 
3.4.5 Oxaliplatin  
3.4.5.1 Peripheral neuropathy 
Oxaliplatin is consistently associated with two types of perip heral neuropathy, which includes 
paresthesia and dysesthesias of the hands, feet, and peri -oral region. Patients treated with  
oxaliplatin in this study will b e counseled to avoid cold drinks and exposure to cold water or air, 
especially for 3 to 5 days fol lowing oxaliplatin administration.  
3.4.5.1.1 Neurologic Toxicity Scale for Oxaliplatin Dose Adjustments 
Description  Grade  1st occurrence  2nd occurrence  3rd occurrence  
Paresthesia /dysesthesia s that 
do not interfere with function  1 no dose reduction  no dose reducti on  no dose reduction  
Paresthesia /dysesthesias, 
interfering with function, but 
not activities of daily living 
(ADL)  2 no dose reduction  no dose reduction  100 mg/m2  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
26 Description  Grade  1st occurrence  2nd occurrence  3rd occurrence  
Paresthesi a/dysesthesias b 
with pain or with functional 
impairment that also 
interfer e with ADL  3 no dose reduction  100 mg/m2  Stop treatment 
permanently  
Persistent 
paresthesia/dysesthesias that 
are disabling or life-
threat ening  4 Stop tr eatment 
permanently  Stop treatment 
permanently  Stop treatment 
permanently  
ACUTE: (during or af ter the 2 -hour 
infusion) laryngopharyngeal 
dysesthesias  increase duration 
of next infusion to 
6 hours  N/A  N/A  
 
3.4.5.2 Laryngopharyngeal dysesthe sias 
An unusual laryngopharyngeal dysesthesia, a loss of sensation of breathing (acute respiratory 
distress) witho ut any objective evidence of respiratory distress (hypoxia, laryngospasm, or 
bronchospasm), also has been observed. This neurotoxicity may be induced or exacerbated upon exposure to cold. 
If a patient develops laryngopharyngeal dysesthesia, the patient’s oxygen saturation should be 
evaluated via a pulse oximeter and, if normal, reassurance, a benzodiazepine or other anxiolytic agent should be considered and the  patient should be observed in the clinic until the episode has 
resolved. The oxaliplatin infusion may then be continued at 1/3 the rate. Because this syndrome 
may be associated with the rapidity of oxaliplatin infusion, subsequent doses of  oxaliplatin 
should be administered as 6-hour infusions (instead of the normal 2-hour infusion). 
Patients on oxaliplatin should not receive cold drinks or ice chips on Day 1 of each cycle as this 
may exacerbate oral or throat dysesthesias, as well as laryn gopharyngeal dys esthesia.  
3.4.5.3 Allergic reactions 
For Grade 1 or 2 acute hypersensitivity reactions, no dose modification of oxaliplatin is required if, in the investigator’s opinion, it is in the patient’s best interest to continue. Pre- medication with 
dexamet hasone 20 mg IV, diphenhydramine 50 mg IV, and one of the following: cimetidine 300 
mg IV, ranitidine 50 mg IV, or  famotidine 20 mg IV 30 minutes prior to study drug 
administration is suggested. If an allergic reaction persists into the next cycle, administer 50 mg dexamethasone PO 12 hours and 6 hours prior to administration of oxaliplatin. 
For Grade 3 or 4 acute hypersensitivity reactions, treatment with oxaliplatin should be 
discontinued. 
3.4.6 Pembrolizumab  
The following broad guidelines for dose delivery sc hedule delays an d alternations apply to 
pembrolizumab and are dependent on the clinical and laboratory assessment on the day of 
dosing. Pembrolizumab can be delivered within 72 hours of planned interval to accommodate 
scheduling issues/logistics.  Based on  the mechanism o f action of pembrolizum ab leading to T -cell activation and 
proliferation, there is the possibility  of observing irAEs during the conduct of this study. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
27 Potential irAEs may be similar to those seen with the use of ipilimumab, BMS -936558 (ant i-PD-
1 mAb), and  BMS -936559 (anti -PD-L1 mAb) and may include immune -mediated enterocolitis, 
dermatitis, hepatitis (hepatotoxicity), and endocrinopathies [6, 59, 60]. These AEs are 
inflammatory in nature and can affect any organ.  
Subjects should be monitored for signs and symptoms of irAEs. In the absence of an a lternate 
etiolog y (e.g., infection or PD), an immune -related etiology should be considered for signs or 
symptoms of enterocolitis, dermatitis, hepatitis, and endocrinopathy. In addition to the dose 
modifications shown in  Table 1, it is recommended that management  of irAEs follow the 
guidelines outlined for ipilimumab [81]. These guidelines recommend the following: 
1. Subjects sh ould be evaluated to identify any alternative etiology 
2. In the absence of clear alternative etiology, all events of  an inflammatory nature should 
be considered to be immune- related  
3. Symptomatic and topical therapy should be considered for low grade events (a ll Grade 1 
event s, dermatologic and pruritus Grade 2 events). 
4. Systemic corticosteroids should be considered for a persistent low -grade event or for a 
more severe event  
5. More potent immunosuppressives should be considered for events not responding to system ic steroids (e.g ., infliximab, mycophenolate, etc.).  
Dose modifications will not be required for AEs that are clearly not attributed to pembrolizumab (such as an accident) or for laboratory abnormalities that are not deemed to be clinically significant , or which are ascri bable to CAPOX. Dose reductions of pembrolizumab are not 
permitted.  
General guidelines regarding dose modification are provided in Table 1. All toxicities will be 
graded according to NCI CTCAE v4.0. 
Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons 
not related to study therapy (e.g., elective surgery, unrelated medical events, patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 weeks of the scheduled interruption. The reason for interruption should be documented in the patient's study 
record.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
28 Table 1: Dose Modification Guidelines for Drug -Related Adverse Events , version 10-22-2017 
General instructions:  
1. Corticosteroid taper shou ld be initiated upon AE improving to Grade 1 or less and continue to taper over at least 4 weeks.  
2. For situations where pembrolizumab has been withheld, pembrolizumab can be resumed after AE has been reduced to Grade 1 or 0 and 
cortic osteroid has been tapered. Pembrolizumab should be permanently discontinued if AE does not resolve  within 12 weeks of last dose or 
corticosteroids cannot be reduced to ≤10 mg prednisone or equivalent per day within 12 weeks.  
3. For severe and life- threatenin g irAEs, IV corticoster oid should be initiated first followed by oral steroid. Other immunosuppres sive treatment 
should be initiated if irAEs cannot be controlled by corticosteroids.  
 
 
Immune -related 
AEs Toxicity grade or 
conditions 
(CTCAEv4.0)  Action tak en to 
pembrolizumab irAE management with 
corticosteroid and/or other 
therapies  Monitor and follow -up  
Pneumonitis  Grade 2  Withhold  • Administer corticosteroids (initial 
dose of 1 -2 mg/kg prednisone or 
equivalent) followed by taper  
 • Monitor participants f or signs and 
symptoms of pneumonitis  
• Evaluate participants with suspected 
pneum onitis with radiogr aphic imaging and 
initiate corticosteroid treatment 
• Add prophylactic antibiotics for 
opportunistic infections  Grade 3 or 4, or recurrent Grade 2  Permanently  
discontinue  
Diarrhe a / Colitis  Grade 2 or 3  Withhold  • Administer corticoste roids (initial 
dose of 1-2 mg/kg prednisone or 
equivalent) followed by taper  
 • Monitor participants for signs and symptoms 
of enterocolitis ( i.e., diarrhea, abdominal 
pain, blood or mucus in stool with or 
without fever) and of bowel perforation 
(i.e., peritoneal signs and ile us). 
• Participants with ≥ Grade 2 diarrhea 
suspecting colitis should consider GI consultation and performing endoscopy to rule out colitis.  
• Participants with diarrhea/colitis should  be 
advised to drink liberal quantities of clear fluids.   If sufficient ora l fluid intake is not 
feasible, fluid and electrolytes should be 
substituted via IV infusion.  Grade 4  Permanently discontinue  
AST / ALT elevation or Grade 2  Withhold  • Administer corticosteroids (initial 
dose of 0. 5- 1 mg/kg prednisone or 
equivalent) followed by taper  • Monitor with liver function tests (consider 
weekly or more frequently until liver 
enzyme value returned to baseline or is 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
29 Immune -related 
AEs Toxicity grade or 
conditions 
(CTCAEv4.0)  Action tak en to 
pembrolizumab irAE management with 
corticosteroid and/or other 
therapies  Monitor and follow -up  
Increased 
bilirubin  Grade 3 or 4  Permanently 
discontinue  • Administer corticosteroids (init ial 
dose of 1 -2 mg/ kg prednisone or 
equivalent) followed by taper  stable  
Type 1 diabetes mellitus (T1DM) 
or Hyperglycemia  
 Newly onset 
T1DM or  
Grade 3 or 4 
hyperglycemia associated with 
evidence of β -cell 
failure  Withhold  • Initiate insulin replacement 
therapy f or participants with 
T1DM  
• Administer anti- hyperglycemic in 
participants with hyperglycemia  
 • Monitor participants for hyperglycemia or other signs and symptoms of diabetes.
 
Hypophysitis  Grade 2  With hold • Administer corticosteroids and 
initiate hormonal re placements as 
clinically indicated.   
 • Monitor for signs and symptoms of hypophysitis (including hypopituitarism and adrenal insufficiency)  
 
Grade 3 or 4  Withhold or permanen tly 
discontinue1  
Hyperthyroidism  Grade 2  Continue  • Treat with non -selectiv e beta -
blockers ( e.g., propranolol) or 
thionamides as appropriate  • Monitor for signs and symptoms of thyroid 
disorders.  
 
Grade 3 or 4  Withhold or  
permanently 
discontinue1 
Hypothyroidism  Grade 2-4 Continue  • Initiate thyroid replacement 
hormones ( e.g., levothyroxine or  
liothyroinine) per standard of care  • Monitor for signs and symptoms of thyroid 
disorders.  
 
Nephritis and Renal dysfunction  Grade 2  Withhold  
• Administer cort icosteroids 
(prednisone  1-2 mg/kg or 
equivalent) followed by taper.  • Monitor cha nges of renal funct ion 
 
Grade 3 or 4  Permanently 
discontinue  
Myocarditis  Grade 1 or 2  Withhold  • Based on severity of AE 
administer corticosteroids  • Ensure adequate evaluatio n to confirm 
etiology a nd/or exclude other causes  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
30 Immune -related 
AEs Toxicity grade or 
conditions 
(CTCAEv4.0)  Action tak en to 
pembrolizumab irAE management with 
corticosteroid and/or other 
therapies  Monitor and follow -up  
Grade 3 or 4  Permanently 
discontinue   
All o ther 
immune -related 
AEs Intolerable/ 
persistent Grade 2  Withhold  • Based on type and severity of AE 
administer corticosteroids  • Ensure adequate evaluation to co nfirm 
etiology and/or e xclude other causes  
 Grade 3  Withhold or 
discontinue based on the type of  
event.  Events that require 
discontinuation 
include and not limited to:  Gullain -Barre 
Syndrome, 
encephalitis  
Grade 4 or 
recurrent Grade 3  Permanently 
discontinue  
1. Withhold or permanently discontinue pembrolizumab is at the discr etion of the invest igator or treating physician.   
NOTE:  
For participants with Grade 3 or 4 immune -related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be resumed 
when AE resolves to ≤ Grade 2 and is controlled with hormon al replacement ther apy or achieved metabolic control (in case of T1DM).   
 
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
31 3.5 STUDY CALENDAR  
 Screening  Baseline  Cycles 1 -65 Cycle 7 - to 
PD5 EOT9 Follow 
Up10 
Pembrolizumab 1   X X   
Oxaliplatin2   X    
Capecitabine3   X    
Informed consent  X      
Medical history 4  X X     
Concomitant meds    X X   
Adverse event 
evaluation    X X X  
Physical exam 4 X X X X X  
Vital signs4 X X X X X  
Height  X      
Weight4 X  X X   
Performance  
Status4  X  X X X  
CBC w/differential,  
Platelets 4 X  X13 X13 X  
PT, INR, PTT, 
Fibrinogen    X13 X13 X  
Serum chemistry 4, 
12 X  X13 X13 X  
HIV, Hepatitis B 
and C serology 
and/or viral load  X      
HLA   X     
Thyroid Panel   X13 X13 X  
TB testing (if clinically indicated)
 X      
Serum or urine 
pregnancy test4 X X     
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
32  Screening  Baseline  Cycles 1 -65 Cycle 7 - to 
PD5 EOT9 Follow 
Up10 
Tumor markers: 
aFP, CEA or Ca 
19.94   X13 X13   
EKG4 X X     
Confirmation of dx by NCI LP X      
Restaging radiologic 
Evaluation4  X X X6 X6   
Optional Tumor 
biopsy   X X7    
Immune monitoring 
11   X X   
Blood for TCR beta 
sequencing14   X X   
Advance Directive8  X     
Annual telephone 
contact       X 
1 200 mg of Pembrolizumab will be administered as a 30 -minute IV  infusion Day 1 of each 
cycle.  
2 Oxaliplatin will be adm inistered on D1 of each cycle at a dose of 130mg/m² IV 
3 Capecitabine will be administered at a do se of 750 mg/m2 PO every 12 hours. Doses will be 
rounded downward to the nearest 150 mg. Patients will begin Capecitabine dosing on the D ay 1 
of each cycle an d will continue to rece ive Capecitabine for 14 days. 
4 Tests performed  at scree ning do not need to be repeated on baseline or Cycle 1 Day 1 if 
performed in designated time frame  
5 Each cycle is 21 days. Trial treatment may be administered up to 3 days bef ore or after the 
schedu led Day 1 of each cycle due to administrative reasons.  
6 CT/PET/MRI of che st abdomen and pelvis. Restaging scan s every 9 weeks +/ - 7 days. 
7 Performed on  cycle 3 Day 1  only +/ - 7 days 
8 As indicated in section  10.3, all subjects will be offered the opportunity to complete an NIH 
Advance Directive form.  This should be done preferably at baseline but can be done at any time 
during the study as long as the capacity to do so is retained. The completion of the form i s 
strongly recommended but is not required. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
33 9 The off- treatment  visits/labs  will occur if patient is agreeable to coming back and physically 
able to return for the visit. This visit may should occur around day 30 post the last dose of study 
drug. If toxicities cause discontinuation of therapy, patients will be followed until resolution of toxicity to at least Grade 1. If the patient cannot return to the Clinical Center for this visit, a request will be made to collect required clinica l labs from a local physician or laboratory. If this 
is not possible, patients may be assessed by telephone for symptoms. 
10 Follow-up will be annual telephone contact to assess survival status. Every attempt will be 
made to contact patient/subject including: contacting referring physician, contacting emergency contact patient identified on admission, checking SSDI (Social Security Death Index)  
11 Immune monitoring on Day 1 of cycles 1 -4, then every 12 weeks until PD , +/-48 hours’ time 
window applies  
12 Electrolytes, BUN, creat inine, AST, ALT, total and direct bilirubin, calcium, phosphorus, 
albumin, magnesium, uric acid, amylase.  Uric acid and  amylase do not need to be done on 
screening  
13 Within 48 hours prior to study drug 
14 D1 of each cycle until PD , +/-48 hours’ time window applies  
3.6 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to removal from study, effort must be made to have all subjects complete a safety visit approximately 30 days following the last dose of study therapy 
3.6.1 Criteria for R emoval fr om Protocol T herapy  
Treatment  may continue until one of the following crite ria applies:  
• Disease progression  (per immune -related response criteria).  
• Intercurrent illness that prevents further administration of treatment  
• Unacceptable toxicity as defined in s ection  3.4 
• Participant request s to be withdrawn from active therapy 
• General or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigato r 
• Delayed recovery from toxicity that prevents re -treatm ent in ≤  28 days of  scheduled 
therapy  
• Investigator discretion  
• Positive pregnancy test 
3.6.2 Off-Study Criteria  
• Participant requests to be withdrawn from study 
• Investigator discretion  
• Death  
• PI decision to end the study 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
34 3.6.3 Off-Study Procedure 
Authorized staff must notify Central Regis tration Office (CRO) when a subject is taken off 
protocol therapy and when a subject is taken off-study. A Participant Status Updates Form from 
the web site (http://home.ccr.cancer.go v/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted email to:  NCI Central Registration Office 
ncicentralregistration -l@mail.nih.gov . 
4 CONCOMITANT MEDICATIONS/MEASURES  
All routine and appropriate supportive care (including blood products) will be provided during 
this study, as clinically indicated, and in accordance with the standard of care p ractices.  Clinical 
judgment should be utilized in the tr eatment of any AE experienced by the patient. 
Information on all concomitant medications, administered blood products, as well as interventions occurring during the study must be recorded on the patient’s eCRF.  
4.1 S
UPPORTIVE CARE GUIDELINES  
Subjects should re ceive appropriate supportive care measures as deemed necessary by the 
treating investigator.  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below. Where appropriate, these guidelines  
include the use of  oral or intravenous treatment with corticosteroids as well as additional anti-
inflammatory agents if symptoms do not improve with administration of corticost eroids. Note 
that sever al courses of steroid tapering may be necessary as sympt oms may worsen when the 
steroid dose is decreased. For each disorder, attempts should be made to rule out other causes such as metastatic disease or bacterial or viral infection , which might require a dditional 
supportive care. The treatment guidelines are intended to be applied when the investigator 
determines the events to be related to pembrolizumab.  
Note: if after the evaluation the event is determined not to be related, the investigator does not 
need to follow the treatment guidance (as outlined below).  It may be necess ary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event.  4.1.1 Pneumonitis:  
• For Grade 2 even ts, treat with systemic  corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. 
• For Grade 3 -4 events, immediately treat with intravenous steroids.  Administer additional 
anti-inflammatory measures, as needed. 
• Add prophylactic antibiotics for opportunistic infe ctions in the case of prolonged steroid 
administration.  
4.1.2 Diarrhea/Colitis  
• Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as 
diarrhea, abdominal pain, blood or mucus in stool, with or without fever) and of bowel perfora tion (such as peritoneal signs and ileus).  
• All subjects who experience diarrhea/colitis should be advised to drink liberal quantities of clear fluids.  If sufficient oral fluid intake is not feasible,  fluid and electrolytes should 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
35 be substituted via IV inf usion. For Grade 2 or higher diarrhea, consider GI consultation 
and endoscopy to confirm or rule out colitis. 
• For Grade 2 diarrhea/ colitis, administer  oral corticosteroids.  
• For Grade 3 or 4 diarrhea/ colitis, treat with intravenous steroids followed by high dose 
oral steroid s.  
• When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks. 
4.1.3 Type 1 diabetes mellitus  
• (if new onset, including diabetic ke toacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if 
associated with ketosis (ketonuria) or metabolic acidosis (DKA) 
• For T1DM or Grade 3 -4 Hyperglycemia  
• Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.  
• Evaluate patients with serum glucose and a metabolic panel, urine ketones, glycosylated 
hemoglobin, and C-peptide.  
4.1.4 Hypophysitis 
• For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
• For Grade 3 -4 events, treat with an initial dose of IV corticoster oids followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
• Hyperthyroidism or Hypothyroidism  
• Thyroi d disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid di sorders.  
• Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism) 
o In hyperthyroidism, non- selective beta- blockers (e.g. propranolol) are suggested as 
initial therapy.  
o In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothy ronine, is indicated per standard of care. 
4.1.4.1 Grade 3 -4 hyperthyroidism  
Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
36 4.1.5 Hepatic  
• For Grade 2 events, monitor liver function tests more frequently until returned to baseline 
values (consider weekly). 
Treat with I V or oral corticosteroi ds 
• For Grade 3 -4 events, treat with intravenous corticosteroids for 24 to 48 hours.  
• When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over no less than 4 weeks. 
4.1.6 Renal Failure or Nephritis  
• For Grade 2 events, treat w ith corticosteroids.  
• For Grade 3 -4 events, treat with systemic corticosteroids.  
• When symptoms improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 weeks.  
Management of Infusion Reactions: Signs and symptoms usually develop during or shortly after 
drug infusion and generally resolve completely within 24 hours of completion of infusion.  
Table 2 below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK -3475).  
Table 2: Treatment guidelines for those who experience infusion reaction associated with 
pembrolizumab.  
NCI CTCAE Grade  Treatment  Premedication at sub sequent 
dosing  
Grade 1  
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated  Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of 
the investigator.  None  
Grade 2  
Requires infusion interruption but responds promptly to symptomatic treatment (
e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications 
indicated for < =24 hrs. Stop Infusion and monitor symptoms.  
Additional appropriate medical therapy  may 
include but is not  limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medically stable in the opinion of the investigator.  
If symptoms resolve withi n one hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of t he original infusion rate Subject may be pre -medicated 
1.5h (± 30 minutes) prior to 
infusion of pembrolizumab 
(MK -3475) with: 
 
Diphenhydramine 50 m g po (or 
equivalent dose of 
antihistamine).  
 
Acetaminoph en 500 -1000 mg 
PO (or equivalent dose of 
antipyretic).  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
37 NCI CTCAE Grade  Treatment  Premedication at sub sequent 
dosing  
(e.g., from 100 mL/ hr. to 50 mL/ hr.). 
Otherwise dosing will be held until 
symptoms resolve and the subject should be 
pre-medicated for the next schedul ed dose. 
Subjects who d evelop Grade 2 toxicity 
despite adequate premedication s hould 
be permanently discontinued from 
further trial treatme nt administration.  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of inf usion); 
recurrence of s ymptoms following 
initial improvement; 
hospitalization indicated for other 
clinical sequelae (e.g., renal 
impairment, pulmonary infiltrates)  
Grade 4:  
Life-threatening; pressor or 
ventilatory support indicated  Stop Infusion.  
Additiona l appropriate medical therapy may 
include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epinephrine  
 
Increase monitoring of vital signs as 
medically indicated until the subject is 
deemed medi cally stable in the opi nion of 
the investigator.  
Hospitalization may be indicated.  
Subject is permanently discontinued 
from further trial treatment 
administration.  No subsequent dosing  
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of drug administration.  
 
 
5 BIOSPECIMEN COLLECTION  
5.1 CORRELATIVE STUDIES FOR RESEARCH  
The correlative studies which we wish to perform are outlined below and summarized in the 
table. A description of each test  including a brief stat ement of rationale and processing 
information is made be low. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
38 Test/assay  Volume blood 
(approx. ) Type of 
tube  Collection point 
(+/- 48hrs)  Location of specimen 
analysis2 
Immune - monitoring  120mls (for 
PBMC)  EDTA  See Study 
Calendar 3.5 Greten Lab  
5-10mls (for 
serum)  EDTA  
Immune cell 
infiltration  (e.g. 
CD3+ CD4/8 cells 
etc.) as well as other surface markers 
such as PD -L1. Optional tumor 
biopsy NA Baseline and Cycle 
3 Day 1 +/- 7 days Greten Lab  
RNA Nanostring 
analysis (nCounterPan Cancer Immunology 
Profile)  Option al tumor 
biopsy  Cycle 3 Day 1 +/ - 
7 days Greten Lab   
TCR beta 
sequencing. Optional tumor 
biopsy  Cycle 3 Day 1 +/ - 
7 days Adaptive 
Biotechnologies1. 
TCR beta 
sequencing. PBMC  EDTA , 5 
ml See Study 
Calendar 3.5 Adaptive Biotechnologies
1  
 
1 Lara Gruye, Adaptive Biotechnologies, 1551 Eastlake Ave E #200, Seattle, WA 98102 (855) 
466-8667. Coded linked samples without key will be sent to Adaptive Biotechnologies . 
2 Blood samples will initially be sent to the Figg laboratory for barcoding and storage.  
5.2 NCI  CORRELATIVE STUDIES  
5.2.1 Immune monitoring 
• We will analyze PBMC for quantitative and functional changes of effector cells as well as analyze sera for cytokines an d chemokines. The effect on (i) CD4 T cell number and 
activity, (ii) CD8 T cell number and activity, (iii) NK cell number and activity, (iv) Treg number, (vi) MDSC: frequency + functional assay, (vii) selected cytokines in serum, and (viii) the detection of tumor -associated antigens using tetramer assay.  
• Patie nts will undergo blood sampling (c.120mls blood) on the ti me points outlined in the 
Study Calendar 3.5. 12 purple EDTA tubes will be  used. Blood will initi ally be sent to 
the Figg laboratory for barcoding and processing. On certain occasions,  the blood may 
also be brought to the Greten lab for processing and analysis.  
• Specimens will be labeled with the study identifier only and will b e shipped to the 
addres s above, either on dry ice or at ambient temperatures as  required by the type of 
sample to be analyzed.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
39 5.2.2 Tumor Biopsy 
An optional tumor biopsy will be performed at baseline for analysis of PD -L1 expression as well 
as other factors such as immune infiltration. We will also attempt an optional CT guided biopsy 
at a subsequent timepoint ( after 6 weeks ) if the patient is willing and the procedure can be 
performed safely . Tumor Tissue will be processed by the Department of Pathology, NCI , NIH 
(Dr. David Kleiner) . Two core biopsies will be the attempted. For each specimen obtained the 
core will be divided in two parts for Surgical Pathology and frozen preservation. If for some reason only one core is able to be obtained, the core will be divided, with half submitt ed to 
Surgical Pathology and half used for PD studies. 
1) Formalin -fixed. 
i. The half fixed in 10% formalin will be submitted to Surgical Pathology, CCR/NCI ( Bldg. 10, 2N212).  
ii. The specimens will have routine H&E stains made as well as 5 a dditional 
unstained sections.  
2) Frozen -preservation  
i. Two 1.5 ml cryogenic vials (obtained from Greten lab) will be labeled with the patient’s  name, accession number (HP#) and date using a waterproof sharpie.  
ii. The isotherm flask (Greten lab) will be filled with liquid nitrogen on the morning of the procedure and will be available together with the cryogenic vials when radiology page the contact person to collect the specimens. 
iii. Once the biopsy is ready, the half- core to be cryopreserved will be transferred into  
an empty 1.5-mL cryoge nic vial with the use of sterile, pre -chilled (in dry ic e) 
disposable tweezers.  
iv. The vial with specimen will be immediately dropped into liquid nitrogen contained in an isotherm flask.  
v. The frozen half will be transferred in the isotherm flask to the protocol-specified location for that particular analysis.  
5.2.3 Tum or tissue analysis 
Tumor samples from biopsies will be send to the pathology for cancer evaluation, only leftover samples will be used for research .  
(i) IHC will be performed on tumor tissue for asse ssment of immune cell infiltration ( e.g. CD3+ 
CD4/8 cell s etc.) as well as other surface markers such as PD -L1. 
(ii) Tumor samples will also be used for Nanostring analysis (nCounterPan Cancer Immunology 
Profile) and TCR beta sequencing. For TCR (cell rece ptor) gene usage may be quantitated in 
samples using conventional sequencing techniques of the T cell receptor variable region of the beta chain as is  specified in Material Transfer Agreement  between NCI and Adaptive 
Biotechnologies. Fewer than 100 genes will be analyzed. For TCR Beta Sequencing the NCI 
Thoraci c and GI Oncology Branch will release coded tumor and PBMC samples collected in 
association with this protocol to: Lara Gruye, Adaptive Biotechnologies, 1551 Eastlake Ave E #200, Seattle, WA 98102 (855) 466-8667. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
40 5.3 SAMPLE STORAGE , TRACKING AND DISPOSITION  
Samples will be ordered in CRIS Screens  and tracked through a Clinical Trial Data Management 
system . Should a CRIS screen not be available, the CRIS downtime procedures will be fo llowed . 
All samples will be sent to Blood Processing Core (BPC)  for processing and storage until they 
are distributed to Dr. Greten’s lab sample analysis as described in the protocol. Samples will not 
be sent outside NIH without appropriate approvals and/or agreements, if requir ed.  
5.3.1 Samples Man aged by Dr. Figg’s Blood Processing Core (BPC)  
5.3.1.1 BPC cont act information  
Please e- mail at NCIBloodcore@mail.nih.gov at least 24 hours before transporting samples (the 
Friday before is pr eferred).  
For samp le pickup, page 102-11964. 
For immediate help, call 240-760-6180 (main blood processing core number) or, if no answer, 
240-760-6190 (main clinical pharmacology lab number). 
For questions regarding sample processing, contact NCIBloodcore@mail.nih.gov. 5.3.1.2 Sample Data Collection  
All samples sent to the Blood Processing Core (BPC)  will be barcoded, with data entered and 
stored in the LABrador (aka LabSamples) utilized by the BPC. This is a secure prog ram, with 
access to LABrador limited to defined Figg lab personnel, who are issued individual user 
accounts. Installation of LABrador is limited to computers specified by Dr. Figg. These 
computers all have a password restricted login screen .  
LABrador creates a unique barcode ID for every sample and sample box, which c annot be traced 
back to patients without LABr ador access. The data recorded for each sample in cludes the 
patient ID, name, trial name/protocol number, time drawn, cycle time point, dose, mater ial type, 
as well as box and freezer location. Patient demographics associated with the clinical center 
patie nt number are provided in the system. For each sa mple, there are notes associated with the 
processing method (delay in sample processing, storage conditions on the ward, etc.). 
Sample bar -codes are linked to pat ient demographics and limited clinical information. This 
information will only be provided to investigators listed on this protocol, via registered use of the 
LABrador. It is cri tical that the  sample remains linked to patient information such as race, age,  
dates of diagnosis and death, and histologic al info rmation about the tumor, in order to corre late 
genotype with these variables 
5.3.1.3 Sample Storage  
Barcoded samples are stored in barcoded boxes i n a locked freezer at either - 20 or -80°C 
according to stability requirements. These freezers are located ons ite in the BPC and offsite at 
NCI Frederick Centr al Repository Services in Frederick, MD. Visitors to the laboratory are 
required to be accompanied by laboratory staff at all times.  Access to stored clinical sa mples is restricted. Samples will be stored until re quested by a 
researcher named on the proto col. All requests are monitored and tracked in LABrador . All 
researchers are required to sign a form stating that the samples are only to be used for research 
purposes associated with this trial (as per the IRB app roved protocol) and that any unused 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
41 sample s must be returned to the BPC. It is the responsibility of the NCI Principal Investigator to 
ensur e that the samples requested are being used in a manner consiste nt with NIH Intramural 
IRB approval. 
Followin g compl etion of this study, samples will remain in storage as detailed above. Access to 
these samples will only be granted following NIH Intramural  IRB approval of an additional 
protocol, granting the rights to use the material.  
If, at any time, a patient withdra ws from the study and does not wish for their existing samples to 
be utilized, the individual must provide a written request. Following receipt of this request, the 
samples will be destroyed (or returned to the patient, if so requested). 
The PI will record any loss or unanticipated destruction of samples  as a deviation. Reports will 
be made per the requirements of section 7.2.  
5.3.2 Procedures for Storage of Tissue Specimens in the Laboratory of Pathology 
Tissues designated for clinical diagnostics are transported to the Laboratory of Pathology (LP) 
where they are examined grossly and relevant portions are fixed, embedded in paraffin and 
sectioned and stained for diagnostic interpretation.  Unutilized excess tissue s are s tored for up to 
three months, in accordance with College of American Path ologists/Joint Commission on 
Accreditation of Healthcare Organizati ons (CAP/JCAHO) guidelines, and then discarded. 
Following completion of the diagnostic workup, the slides and tissue  blocks are stored 
indefinitely in the LP’s clinical archives.  All specimens are catalogued and retrieved utilizing the 
clinical laboratory informa tion systems, in accordance with CAP/JCAHO regulations. T he use of 
any stored specimens for research purposes is only allowed when the appropriate IRB approval 
has been obtained. In some cases, this approval has been obtained via the original protocol on 
which the patient was enrolled. 
5.3.3 Procedures for storage of specimens in the Laboratory of Dr. Greten  
Patient sa mples, collected for the purpose of research under IRB approved protocols  where Dr 
Greten is Principal Investigator, may be archived in the Dr Greten laboratory. All data associated 
with archived clinical  research samples is entered into the web -based NCI Labmatrix database, 
centralized system with access controlled via central ized login. Access to this database is limited 
to Dr  Greten  research staff, requiring individual login and password. All staff in t he Dr  Greten  
laboratory have  received annuall y updated NIH/CIT training and maintain standards of comp uter 
security.  
The data recorded for each sample may include the patient ID, trial name/pr otocol number, date 
drawn/collected , treatment cycle/post- transp lant time po int, cell source (e.g. peripheral  blood, 
marrow,  tissue ) as well as box and freezer l ocation. All received samples will receive a unique 
bar code number, which will be added to the sample NCI Lab matrix database. 
Samples are stored in freezers at -80°C (sera, plasma, tissue samples) or under  liquid nitrogen 
(cells), according to stability requirements. These freezers are located onsite at the Dr  
Greten  laboratory. Access to samples f rom a protocol for research purposes  will be by 
permission of the Principal Investigator . 
Contact information: 
Sophi e Wang  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
42 Building 10 Rm 3B44 
Phone: 240-858-3218 E-mail: sophie.wang@nih.gov
 
5.3.4 Protocol Completion/Sa mple Destruction  
All specimens obtai ned in the protocol are used as defined in the protocol. Any specimens  that 
are remaining at the completion of the protocol will be stored in the conditions described in 
section s above. The study will remain open so long as sample or data an alysis continue s. 
Samples from consenting s ubjects will be stored until they are no long er of s cientific value or if a 
subject withdraws consent for their continued use, at which time they will be destroyed.  If the patient withdraws consent the participant’s data will be excluded from future distr ibutions, 
but data that have already been dis tribute d for approved research use will not be able to be  
retrieved.  
The PI will record any  loss or unanticipated destruction of sa mples as a deviation. Reports will 
be ma de per the requirements of section 7.2. 
5.4 S
AMPLES FOR GENETIC /GENOMIC ANALYSIS  
TCR ( cell receptor) gene usage may be quantitated  in samples using conventional sequencing 
techniques of the T cell receptor variable region of the beta chain . Fewer than 100 genes will be 
analyzed. For TCR Beta Sequenci ng the NCI Thoracic and GI Oncology Branc h will release 
coded tumor and PBMC samples to Adaptive Biotechnologies.  5.4.1 Privacy and Confi dentiality of medical information/biological specimens  
Fresh tumor and blood sa mples will be stored in a minus 80 -degree freezer. Initially the samples 
of each patient will be sent  to Dr. Figg’ s lab ( 5.3.1).  At no time will pa tient’s names be used on 
the blood and tissue samples. The molec ular studies will be performed at the Adaptive 
Biote chnologies, 1551 Eastlake Ave E #200, Seattle, WA 98102 (855) 466-8667. S ubject ’s 
genetic data will be deposited in a datab ase such as dbGaP . Although there is controlled access 
to such a database, such a submission carries theoretical risks of reve aling the identity of the 
subject. This is discussed in the consent. 5.4.2 Management of Res ults 
There are not going to be incidental fi ndings in this study and the results of molecular studies 
will not be communicated to the patient.  6 DATA COLLECTION AND EVALUATION  
6.1 D
ATA COLLECTION  
The PI will be respo nsible for overseeing entry of data into an in -house password protected 
electronic syste m (C 3D) and Labmatrix ensuring data accuracy, consistency and timeliness. The 
principal investigator, associate investigators/ research nurses and/or a contracted data manager 
will assist with the data management efforts. All data obtained during the conduc t of the protocol  
will be kept in secure network drives or in approved alternative sites that comply with NIH 
security standards. Pri mary and final analyzed data will have identifiers so that research data can 
be attributed to an individual human subject part icipant.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
43 All a dverse events, including clinically significant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return to baseline or stabilization of event.  
Document AEs from the f irst study intervention, Study D ay 1 of Cycle  1 through 30 days after 
the subject received the last study drug administration . Beyond 30 days after the las t 
intervention, only adverse events which are serious and related to the study intervention need to 
be recorde d.  
An abnormal laboratory value will  be recorded in the database as an AE only if the lab oratory 
abnorma lity is characterized by any of t he follo wing: 
• Results in discontinuation from the study 
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic interven tion 
• Is associated with death or another serious adve rse event, incl uding hospitalization.  
• Is judged by the Investi gator to be of significant clinical impact 
• If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to t he test drug an d about the patient’s 
outcome. 
Grade 1  adverse events will not be recorded. 
End of study procedures: Data will be stored according to HHS, FDA regulations and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of d ata: Should we become aware that a major brea ch in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per 
requirements in section 7.2.1.  
6.2 DATA SHARING PLANS  
6.2.1 Human Da ta Sharin g Plan 
I will share coded, linked human data generated in this research for future research  
− in a NIH -funded or approved public repository clinicaltrials.gov , dbGaP 
− in BTRIS  
− with approved outside collaborators under appropriate agreements  
− in publication and/or publ ic presentations  
at the time of pu blication or shortly thereafter. 
6.2.2 Genomic Data Sharing Plan  
Unlinked genomic data will be deposited in public genomic databases such as dbGaP  in 
compliance with the NIH Genomi c Data Sharing Policy. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
44 6.3 RESPONS E CRITERIA  
For the purposes of this study, patients should be re -evaluated for response every  9 weeks.  In 
addition to a baseline scan, confirmatory scans should also be obtained 4- 8 weeks  following 
initial documentation of obj ective response. 
Response and progression wi ll be evaluated in this study using the new international criteria 
proposed by the revised Response Evaluation Criteria in Solid Tumors  (RECIST) guideline 
(version 1.1) [82]  and Modified Immune -related response criteria (irRC) Appendix B. Changes 
in the largest diameter (unidimensional measurement) of the tumor lesions and the  shortest 
diame ter in the case of malignant lymph nodes are used in the RECIST cri teria.   
6.3.1 Definitions  
Evaluable for toxicity : All patients will be evaluable for toxicity from the time of their first 
treatment with pembroli zumab . 
Evaluable for objective res ponse: Only those patients who  have measurab le disease present at 
baseline, have received at least one cycle of therapy, and have had their disease re -evaluated will 
be considered  evaluable for response.  These patients will have their response classified 
according to the  definitions st ated below.  (Note: Patients who exhibit objective di sease 
progression prior to the end of cycle 1 will also be considered evaluable.) 
Evaluable Non-T arget Disease Response: Patients who have l esions present at baseline that ar e 
evaluable but  do not meet the definitions of measurable disease, have received at least one cycle 
of therapy, and have had their disease re -evaluated will be considered evaluable for non -target 
disease.  The response assessment is based on the presence, absence, or uneq uivocal progres sion 
of the le sions.  
6.3.2 Disease Parameters  
Measurable disease : Measurable lesions are defined as those that can be accurately measured in 
at least one dimension (longest diameter to be recorded)  as >20 mm by chest x- ray, as >10 mm 
with CT scan , or > 10 mm with calipers by cli nical exam.  All tumor measurements must be 
recorded in millimeters  (or decimal fractions of centimeters).  
Malignant lymph nodes. To be considered pathologically enlarged and measurable, a lymph node 
must be >15 mm in short a xis when assessed by CT scan (CT  scan slice thickness recommended 
to be no greater than 5 mm). At baseline and in follow -up, only the short axis will be measured 
and followed. 
Non-measurable disease. All oth er lesions (or sites of disease), including small  lesions (longe st 
diameter <1 0 mm or pathological lymph nodes wi th ≥10 to <15 mm short axis), are considered 
non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory b reast disease, and abdominal mas ses 
(not followed by CT or MRI), are considered as non- measurable.  
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither m easurable nor n on-measurable) since they are, b y 
definition, simple cysts.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
45 ‘Cys tic lesions’ thought to represent cystic metastases can be considered as measurable lesions, 
if they meet the definition of measurability described above. However, if non- cystic  lesions are 
present in the same patient, th ese are preferred for selection as tar get lesions.  
Target lesions.  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesi ons and recorded 
and measured  at baseline.  Target lesions should be selected on the basis of their size (lesions 
with the longest diameter), be representative of all involved organs, but in addition should be 
those that lend themselves to re producible repe ated measurements.  It may be the case that, on 
occasion, the lar gest lesion does not lend itself to reproducible measurement in which 
circumstance the next largest lesion which can be measured reproducibly should be selected.  A 
sum of the di ameters (longes t for non- nodal lesions, shor t axis for nodal lesions) for all t arget 
lesions will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the sum.  The ba seline sum diam eters 
will be used as referen ce to further characterize any objecti ve tumor regression in the measurable 
dimension of the disease. 
Non-target lesions . All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesi ons should be identified as non-t arget lesions and should also be 
recorded at baseline.  Measurements of these lesions are not required, but the presence, absence, 
or in rare cases unequivocal progression of each should be noted throughout follow -up.  
6.3.3 Metho ds for Evaluation of Measurable D isease  
All measurements should be taken and recorded in metric notation using a ruler or calipers. All 
baseline evaluations should be performed as closely as possible to the beginning of treatment and never m ore than 4 weeks before the beginning of the tr eatment.  
The same method of assessm ent and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging- based evaluation is 
preferred to evalu ation by clinic al examination unless the les ion(s) being followed cannot be 
imaged but are assessable by clinical exam.  
Clinical lesions : Clinical lesions will only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥ 10 m m diameter as assessed using cal ipers 
(e.g., skin nodules). In the case of skin lesions, documentation by color photography, including a 
ruler to estimate the size of the lesion, is recommended.  
Chest x -ray: Lesions on chest x- ray are acceptable as measurable lesions when they are cl early 
defined and surrounded by aer ated lung. However, CT is preferable.  
Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based 
on the assumption that CT slice thickness is  5 mm or less.  If CT scans have slice thickn ess 
greater than 5 mm, the minimum siz e for a measurable lesion should be twice the slice thickness. 
MRI is also acceptable in certain situations (e.g. for body scans).  
Use of MRI remains a complex issue.  MRI ha s excellent con trast, spatial, and temporal 
resolution; however, there are many image acquisition variables involved in MRI, which greatly 
impact image quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI 
is variable globally. As with CT, if  an MRI is performed, the tec hnical specifications of the 
scanni ng sequences used should be optimized for the evaluation of the type and site of disease.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
46 Furthermore, as with CT, the modality used at follow -up should be the same as was used at 
baseline and  the lesions should be measur ed/assessed on the same pulse seque nce. It is beyond 
the scope of the RECIST guidelines to prescribe specific MRI pulse sequence parameters for all 
scanners, body parts, and diseases. Ideally, the same type of scanner should be  used and the 
image acquisition protocol should be followed as c losely as possible to prior scans. Body scans 
should be performed with breath-hold scanning techniques, if possible. 
PET- CT: At present, the low dose or attenuation correction CT portion of a combined PET -CT is 
not always  of optimal diagnostic CT quality f or use with RECIST measurements.  However, if 
the site can document that the CT performed as part of a PET -CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast), then the CT portion of the PE T-CT can be 
used for RECIST measure ments and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over time.  Note, however, that the PET portion of the CT 
introduces additional data which may bias an investigator if it is  not routinely or serially 
performe d.  
Ultrasound: Ultrasound is not useful in assessment of lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for 
independent review at a later dat e and, because they are operator de pendent, it cannot be 
guaranteed that the same technique and measurements will be taken from one assessment to the next. If new lesions are identified by ultrasound in the course of the study, confirmation by CT or MRI is  advised.  If there is concern about  radiation exposure at CT, MRI may be used instead of 
CT in selected instances.  
Endoscopy, Laparoscopy : The utilization of these techniques for objective tumor evaluation is 
not advised. Howev er, such techniques may be us eful to confirm complete pathologic al response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint. 
Tumor markers : Tumor markers al one cannot be used to assess res ponse. If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response.  Specific guidelines for both CA -125 response (in recurrent ovaria n cancer) and 
PSA response (in recurrent prosta te cancer) have been published [83-85 ]. In addition, the 
Gynecologic Cancer Intergroup has developed CA -125 progress ion criteria wh ich are to be 
integrated with  objective tumor assessment for use  in first-line trials in ovarian cancer [86]. 
Cytology, Histology: These  techniques can be used to differentia te between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain).  
The cytological confirmation of the neoplastic origin of any ef fusion that appears or worsens 
during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stabl e disease (an effusion may be a side effect of 
the treatment) and progressive dise ase. 
FDG -PET: While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in 
assessment of progression (particularly possibl e 'new' disease).  New lesions on the b asis of FDG -
PET imaging can be identified according to the following algorithm:  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
47 a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion. 
b. No FDG -PET at baseline and a po sitive FDG -PET at follow -up: If the  positive FDG -PET 
at follow -up corresponds to a new site of disease confirmed by CT, this is PD.  If the 
positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additiona l follow -up CT scans  are need ed to determine if there is truly p rogression 
occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG -
PET scan).  If the positive FDG -PET at follow -up corresponds to a pre -existing site of 
disease on CT that is not progres sing on the basis of the anatomic i mages, this is not PD. 
c. FDG -PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or 
scarring.  The use of FDG -PET in this circumstance should be pros pectively described in 
the protocol and supported by disease -specific medical literature for the indication.  
However, it must be acknowledged that both approaches may lead to fa lse positive CR  
due to limitations of FDG -PET and biopsy resolution/sensitivity. 
 Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation corrected image. 
6.3.4 Response Criteria  
6.3.4.1 Evaluation of Target Lesions 
Complet e Response (CR) : Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or non- target) must have reduction in short axis to <10 mm. 
Partial Response (PR) : At least a 30% decrease in  the sum of the  diameters of target lesions,  
taking as reference the baseline s um of diameters.  
Progressive Disease (PD) : At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (this includes the baseline sum if that is the 
smallest on study). In addition to the relative i ncrease of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also 
considered progressions). 
Stable Disease (SD) : Neither sufficient shrinkage to qual ify for PR nor sufficient incre ase to 
qualify for PD, taking as reference the smallest sum of diameters while on study. 
6.3.4.2 Evaluation of Non-Target Lesions 
Complete Response (CR) : Disappearance of all non -target  lesions and normalization of tumor 
marker level. All lymph nodes must be non-path ological in size (<10 mm short axis).  
Note:  If tumor markers are initially above the upper normal limit, they must normalize for a 
patient to be considered in complete clinic al response.  
Non-CR/Non -PD: Persistence of o ne or more non- target lesion(s) and /or maintenance of tumor 
marker level above the normal limits.  
Progressive Disease (PD) : Appearance of one or more new lesions and/or unequivocal 
progression of existing non- target lesions. Unequivocal progression should not normally trump 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
48 target lesion statu s. It must be representative of overall disease status change, not a single lesion 
increase.  
Although a clear progression of “non- target” lesions only is exceptional, the opinion of the 
treating physician should preva il in such circumstances, and the p rogression status should be 
confirmed at a later time by the review panel (or Principal Investigator).  
6.3.4.3 Evaluation of Best Overall Response 
The best overall response is the best response record ed from the start of the trea tment until 
disease progression/rec urrence (taking as reference for progressive disease the smallest 
measurements recorded since the treatment started).  The patient's best response assignment will 
depend on the achievement of both measurement and confirmation criteria.  
For Patients with Mea surable Disease (i.e., Target Disease) 
Target 
Lesions  Non-Target 
Lesions  New Lesions  Overall Response  
Best Overall Response when 
Confirmation is Required*  
CR CR No CR >4 wks. Confirmation** 
CR Non-
CR/Non -PD No PR 
>4 wks. Confirmation** CR Not evaluated  No PR 
PR Non-
CR/Non -
PD/not evaluated  No PR 
SD Non-
CR/Non -
PD/not evaluated  No SD 
Documented at least once > 4 
wks. from baseline** 
PD Any Yes or 
No PD 
no prior SD, PR or CR Any PD*** Yes o r 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for furth er details on what is evidence of a new lesion.  
** Only for non-randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in  non-target lesions may be accepted as 
disease progression.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
49 Note : Patients with  a global deterioration of health status requiring discontinuation of treatment without 
objective evidence of disease progression at that time should be reported as “ symptomatic  
deterioration. ” Every effort should be made  to document the objective progress ion even after 
discontinuation of treatment.  
 
For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
 
6.3.5 Duration of Response 
6.3.5.1 Duration of overall response  
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded)  until the first date that re current or progressive disease is 
objectively documented (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  
The duration of overall CR is measured from t he time measurement criteria are first met f or CR 
until the first date that pro gressive disease is objectively documented.   
6.3.5.2 Duration of stable disease  
Stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements  recorded since the treatment start ed, 
including the baseline measurements.  
6.4 M
ODIFIED IMMUNE -RELATED RESPONSE CRI TERIA (IRRC) 
Modified immune -related response criteria (irRC) will also be employed in this study. This new 
classi fication is based on the recent l earning from clinical studies w ith cancer immunotherapies 
that even if some new lesions appear at the beginning of a treatment or if the total tumor burden 
does not increase substantially, tumor regressions or stabilizations might still occur later. Th e 
irRC were created using bi -dimensional measurements (as previously widely used in the World 
Health Organization criteria). For this trial, the concepts of the irRC are combined with RECIST 1.1 to come up with the modified irR C. Please refer to  Appendi x B, for further details.  
6.5 T
OXICITY CRITERIA  
The following adverse event management guidelines are intended to ensure the safety of each patient while on the study. The descr iptions and grading scales found in the revised NCI Non-Target Lesions  New Lesions  Overall Response 
CR No CR 
Non-CR/non- PD No Non-CR/non- PD* 
Not all evalua ted No not evaluated  
Unequivocal PD Yes or No  PD 
Any Yes PD 
* ‘Non -CR/non-PD’ is preferred over ‘stable disease’ for non-target disease since SD is increasingly used 
as an endpoint for assessment of efficacy in some trials s o to assign this category whe n no lesions can be 
measured is not  advised 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
50 Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate treatment areas should have access to a co py of the CTCAE  version 
4.0. A copy of the C TCA E version 4.0 can be downloaded fro m the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 ).  
7 NIH RE PORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN 
7.1 DEFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Research Events found here . 
7.2 OHSRP  OFFICE OF COMPLIANCE AND TRAINING / IRB REPORTING  
7.2.1 Expedi ted Reporting  
Please refer to the rep orting requirements in Policy 801: Reporting Research Events and Policy 
802 Non- Compliance Human Subjects Research found here . Note: Only IND Safety Repo rts that 
meet the defin ition o f an unanticipated problem will need to be reported per these policies. 
7.2.2 IRB Requirements for PI Reporting at Continuing Review 
Please refer to the reporting requirements in Policy 801: Reporting Res earch Events found here .  
7.3 NCI  CLINICAL DIRECT OR REPORTING  
Problems expedi tiously reported to the OHSRP in iRIS will a lso be reported to the NCI Clinical 
Director.  A separate submissio n is not necessary as reports in iRIS will be available to the 
Clinical Director.  
In addition to those reports, all d eaths that occur within 30 days  after  receiving a research 
intervention s hould be reported via email to the Clinical Director  unless they a re due to 
progre ssive disease.    
To report these deaths, please send an email describing the circumstances of the death to Dr. Dahut at NCICCRQA@mail.nih.gov
 within o ne business day of learning of the death . 
7.4 NIH REQUIRED DATA AND SAFETY MONITORING PLAN  
The clinical research team will meet on a regular basis when patients are being actively treated on the trial to discuss each patient.  
All data will be collected in a timely manner and reviewed by the principal investigator or a lead 
associate investigator. Events meeting requirements for expedited reporting as described in 
section 7.2.1 will be submitted within the appropriate timelines .  
The principal investigator will re view adverse event and response data on each patient to ensure 
safety and data accuracy. The principal investigator will perso nally conduct or supervise the 
investigation and provide appropriate delegation of responsibilities to other members of the research staff . 
7.5 S
AFETY REPORTING  CRITERIA TO THE PHARMACEUTICAL COLLABORATOR  (MERCK ) 
7.5.1 Auditing and Monitoring.  
With reasonable advance notice and at reasonable t imes, during and after the completion of the 
Protocol, NCI will permit Collaborator or its design ee(s) to access the NIH Clinical Center to 
audit the conduct of the research, as well  as to audit source documents containing Raw Data, to 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
51 the extent necessary  to verify compliance with FDA Good Clinical Practice (International 
Conference on Harmonization  (ICH ) E6: “Good Clinical Practice: Consolidated Guidance; 62 
Federal Register 25, 691 (1997)) and the Protocol(s)”. 
7.5.2 Safety Reports . 
The Principal Investigator will report to Merck  all SAEs which involve death or a life -
threatening event which are deemed to  be possibly, probably, or definitely related to  
Pembrolizumab  within two (2) calenda r days of receipt of these eve nts by the Prin cipal 
Investigator. The Principal Investigator will use its best efforts to report other SAEs whether or not related to  
Pembro lizumab to the Collaborator within six (6) calendar days of receipt of these events b y the 
Principal Investigator . Adverse Event r eports of cancer will be prov ided to Merck  when the 
Principal Investigator  receives them. The Collaborator Global Safety depar tmen t will receive 
Adverse Experience Reports, from the Principal Investigator  via fax (215 -993- 1220) or secure 
email (aer_mailbox @me rck.com). Data exchange of  individual adverse event reports exchanged 
will be confirmed within one (1) business day. If confirm ation is not received, then the Principal 
Investigator will contact Collaborator to determine if the original r eport needs to be re -sent.  
8 STATISTICAL CONS IDERATIONS   
The primary objective of this study is to determine in a preliminary, limited size tr ial whether 
Pembroli zumab in combination with CAPOX is associated with a 5 -month progression free 
probability, which exceeds 25% when used to treat patients with biliary tract cancer.  
Based on our analysis of data from previous trials of patients with sim ilar eligibility requirements 
the median progression free survival in biliary tract carcinoma is 2.5 months. This t ranslates to 
25% without progressive disease  at 5 months following an exponential failure model. Based on 
these results, it would be useful to demonstrate whethe r Pembrolizumab in combination with 
CAPOX is able to be associated with a median PFS of 5 months, which would correspond to 
50% of patients  having stable disease at 5 months. The trial will be conducted using a two- stage 
optimal design (Sim on R, Controlled Clinical Trials, 10:1 -10, 1989). In order to attempt to 
determine if the agent offers any improvement, using alpha=0.10 and beta =0.10 as acceptable 
error probabilities, the trial will target 50% as the desirable proportion of patients  who are still 
witho ut progression at the five -month evaluation (p1=0.50), and will be considered inadequate if 
only a fraction co nsistent with 20% are without  progression by the same evaluation time 
(p0=0.20). 
Initially, 10 patients will be enrolled and e valuated for progres sion. Enrollment will be 
temporarily halted after the 10th patient has been accrued, unless we know that 3 pat ients have 
passed the 5-month poi nt without progression. If 3 or more of the first 10 patients enrolled have 
not progressed at  the 5- month evaluation, then accrual will continue until a total of 17 patients 
have been entered.  If, among the f irst 10 patient s accrued, 0 to 2 are able to be progression- free 
at the 5-month evaluation, then no further patients will be enrolled after s uch a determination has 
been made. If 6 or more of the total cohort of 17 patients have been found to be progression- free 
at 5 months, then this will indicate an adequate progression free probability to justify further 
consideration of Pembrolizumab in com bination with CAPOX in this population of patients. On 
the other hand, if 3 to 5 of 17 are progression- free at 5 mo nths, this will be considered 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
52 insufficient.  Under the null hypothesis ( 20% progression free at 5 months), the probability of 
being able to stop a ccrual after 10 patients have been evaluated at 5 months is 68%.  
In addition to evaluation of the proportion of patients that  are progression -free at 5 mo nths, the 
progression- free survival for patients will also be analyzed via a Kaplan -Meier curve. This  curve 
will be compared informally to other published results in similar patients. As well, the overall 
respons e rate will be reported, and the overall survival will be reported using a Kaplan -Meier 
curve.  It is anticipated that up to 10 patients per y ear will be able to e nroll onto this protocol.  
Thus, it is expected that accrual of up to 17 total patients can be completed in approximately 2 years. In order to a llow for a small number of unevaluable patients, the accrual ceiling will be set 
at 19 patients. 
To evaluate the response rate, proportion of patients obtaining CR and PR p er RECIST 1.1 
criteria of all evaluable patients wi ll be analyzed.  
To address s afety, tolerability and feasibility of Pembrolizumab in combination with CAPOX 
chemotherapy , adverse events will be tabulated by grade according to CTCAE and analyzed and 
reported descriptively. 9 COLLABORATIVE AGREEMENTS  
9.1 C
OOPERA TIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)  
A CRADA (03145) is in place with Merck  for the supply of the commercial agent  
pembrolizumab. 
9.2 MATER IAL TRANSFER AGREEMENT  
MTA  (40860-16) is in place with Adaptive Biotechnologies   
10 HUMAN SUBJECTS  PROTECTIONS  
10.1 RATIONALE FOR SUBJECT SELECTIO N 
Subjects treated on this study, will be individuals with advanced biliary tract carcinoma , whi ch 
has recurred (or p ersisted) after appropriate standard treatment.  Individuals of any race or ethnic 
group will be  eligible for this study. Eligibility assess ment will be based solely on the patient’s 
medical status.  Recruitment of patients onto this stu dy will be through standard CCR 
mechanisms.  No special recruitment efforts will be conducted.  
10.2 PARTICIPATION OF CHILD REN 
Individuals under the age of 18 will not  be eligible to participate in this study because they are 
unlikely to have biliary tract carcin oma,  and because of u nknown toxicities in pediatric patients. 
10.3 PARTICIPATION OF SUBJ ECTS UNABLE TO GIVE CONSENT  
Adult s unable to give consent are excluded from enro lling in the protocol.  However , re-consent 
may be necessary and there is a possibility, though unlikely, that subj ects could become 
decisional  impaired. For this reason and because there is a prospect of direc t benefit from 
research participation (secti on 10.4), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance 
Direct ive for Health Care and Medical Research Par ticipation” form so that another person can 
make decisions about their medical care in the event  that they become inc apacitated or 
cognitively impaired during the course of the study. Note: The PI or AI will cont act the NIH 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
53 Ability to Consent Assessment Te am (ACAT)  for evaluation  as needed for the following: an 
independent assessment of whether an indivi dual has the capacity to provide consent; assistance 
in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the 
capacity  to appoint a surrogate . For those subjects that become incapacitated and do not have 
pre-determi ned substitute decision maker, the procedures described in NIH HRPP SOP 14E for 
appointing a  surrogate deci sion maker for adult subjects  who are (a) decisional  impaired, and (b) 
who do not have a legal guardian or durable power of attorney, will be foll owed. 
10.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  FOR ALL PARTICIPANT S 
10.4.1 Risk of Optional Biopsy  
All care will be taken to minimize risks that  may be incurred by tumor sampling. However, there 
are procedure -related risks (such as bleeding, infection and vi sceral injury) that will be explained 
fully during informed consent. 
10.4.2 Risks of exposure to ionizing radiation  
This research study involves two  CT guided biopsies collected for research purposes only. 
Subjects undergoing two optional biopsy collections will be exposed to 1.5 rem. This amount of 
radiation is below the guideline of 5 rem per year allowed for adult research subjects by the NIH 
Radiation Safety Committee.  
10.4.3 Research Blood Collection Risks 
Risks of blood draws include pain and bruising in the area whe re the needle is placed, 
lightheadedness, and rarely, fainting. When large amounts of blood are collected, low red blood cell count (anemia ) can develop.  
10.4.4 Other Risks 
Potential risks include the possible occurrence of any of a range of side effects whi ch are listed 
in section 11 and in the Consent Document.  The proce dure for protecting against or m inimizing 
risks will be to medically evaluate patients on a regular basis as described.  
10.4.5 Benefits  
The potential be nefit to a patient that goes onto study is a reduction in the bulk of their tumor 
which may or may not have favorable impact on symptoms and/o r survival.  
10.5 C
ONSENT PROCESS AND DOCUMENTATION  
The procedures and tests involved in this study and the  associated risk s, discomforts and benefits 
of these processes, will be carefully explained to the patient and a signed informed consent document will be obtained prior to entry onto the study. 
For the optional biopsies for research in the protoc ol, the patient will consent at the time of the 
procedure with the original form going to Medical Records and a  copy placed in the research 
record.  If the patient refuses the optional biopsy at that time, the refusal will be documented in 
the medical recor d and in the research record.  
10.5.1 Re-Consent via Teleph one 
Consent via telephone may only be used when re -consent is required, and the patient is not 
scheduled to come for a clinic visit in a timely fashion . 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
54 Telephone consent will be obtained and documented per OHSRP/IRBO and CCR policies and 
procedures . 
11 PHARMACEUTI CAL INFORMATION  
Pembrolizumab  (Keytruda) is approved for the treat ment of patients with metastatic melanoma, 
NSCLC and HNSCC.  
Oxalipl atin is approved for the treatment of patients with advanced colon and col orectal cancer.  
Capecitabine is approved for the treatment of patients with adjuvant colon, metastatic colorectal 
and metastatic breast cancer.  
None of these drugs are approved for t he treatment of patients with a dvanced biliary tract  
carcinoma, the use in  the current pr otocol. The investigation is not intended to support a new 
indication for use or any other significant changes to labeling or advertising in any of the commerci al agen ts used on the study. The investigation does not involve a route of 
admini stration or dos age level i n use in a patient  population or other factor that significantly 
increases the risks (or decreases the acceptability of the risks) associated with the use o f the drug 
products.  
11.1 P
EMBROLIZUMAB  
The investigator shall take responsibility for and shall take al l steps to maintain appropriate 
records  and ensure appropriate supply, storage, handling, distribution and usage of 
investigational product in accord ance wi th the protocol and any applicable laws and regulations. 
Clinical Supplies  will be provided by Merck  as summarized in  Table 3. 
Table 3: Product Descriptions  
Product Name & Potency  Dosage Form 
Pembrolizumab  50 mg Lyophilized Powder for Injection 
Pembrolizumab  100 mg/ 4mL  Solution for Inje ction  
11.1.1 Packaging and L abeling Information 
Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
11.2.1 Drug Product   
Pembrolizumab (MK-3475) Solution for Infusion, 100 mg/ 4 mL vial Pembrolizumab (MK-3475) Solution for Infusion is a sterile, non-pyrogenic aqueous solution 
supplied in single-use Type I glass vial containing 100 mg/4 mL of pembrolizumab (MK-3475). 
The product is preservative-free solution which is es sentially free of extr aneous particulates.  
Cap color of MK- 3475 (P embrolizumab) 100 mg vials: 
Both red and salmon color caps may be used. Though the cap color may be different, the product inside t he vial  is the same MK -3475 drug product. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
55 11.1.2 Stability and Han dling of Drug Product  
Pembrolizumab (MK -3475) Solution for Infusio n, 100 mg/ 4 mL vial : pembrolizum ab (MK -
3475) Solution for Infusion vials should be stored at refrigerated conditions (2 – 8 °C) an d 
prote cted from light.  
Note : vials should be stored in the original box to ensure the drug product is prot ected from light.  
Pembrolizumab (MK-3475)  infusion solutions should be prepared in 0.9% Sodium Chloride 
Injection, USP  (normal saline) or regional equivalent or 5% Dextrose Injection, USP (5% 
dextrose) or reg ional equivalent and t he final concen tration of pembrolizumab (MK-3475)  in the 
infusion solutions should be between 1 mg/mL and 10 mg/mL.  
Please note, the preferred diluent is 0.9% Sodium Chloride and 5% dextrose is only permissible 
if normal saline is no t available.  
Local guidelines should be followed for collection of  diluent information such as manufacturer, 
lot and expiry. When the diluent is provided by Merck, the drug accountability log should be used for collection of diluent information. 
Pembrolizu mab (MK -3475)  SHOULD N OT BE MIXED WITH OTHER DILUENTS.  
Pembrolizu mab (MK -3475) solutions may be st ored at room temperature for a cumulative time 
of up to 4 hours. This includes room temperature st orage o f admixture solutions in the IV bags 
and the duration of infusion In addit ion, IV bags may be stored under refrigerati on at 2 °C to 8 °C (36 °F to 46 °F) for up to 
20 hours. If refrigerated, allow the IV bags to come to room temperature prior to use.  Parenteral drug products should be inspected visually for particulate matter and discoloration 
prior to administration. Discard the drug produc t vial if extraneous particulate matter other than 
translucent to white proteinaceous particles is observed. 
Sites sh ould follow their SOPs for drug transport and delivery, with all possible effort to 
minimize agitati on of the drug product between the phar macy and the clinic  
• Do not use PEMBROLIZUMAB (MK-3475) if discoloration is observed. 
• DO NOT SHAKE OR FREEZE THE VIAL( S). 
• DO NOT ADMINISTER THE PRODUCT AS AN (INTRAVENOUS  (IV) PUSH OR 
BOLUS).  
• DO NOT COMBINE,  DILUTE OR ADMINISTER IT AS AN I NFUSION WITH 
OTHER  MEDICINAL P RODUCTS.  
• Any departure from the guidance listed in this manual, must be discussed with sponsor 
11.1.3 Clinical S upplies Disclosure 
This trial is open -label; therefo re, the subject, the t rial site perso nnel, the Sponsor and/or 
designee are not blinded to treatment. Drug identity (name, strength) is included in the label text; 
random code/disclosure envelopes or lists  are not provided. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
56 11.1.4 Storage and Handling Requirements 
Clinical supplies mus t be stored in a secure, l imited -access locatio n under the storage conditions  
specified on the label.   
Receipt and dispensing of trial medication must be recorded by an authorized pe rson at the trial 
site. 
Clinical supplies may not be used for any purpose other than that stated in the protocol. 
11.1.5 Retu rns and Reconciliatio n 
The investigator is responsible for keeping accurate records of the clinical supplies received from 
Merck  or design ee, the amount dispensed to and returned by the subjects and the amount 
remaining at the conclusion of the trial.  
Upon com pletion  or termination of the study, all unused and/or partially used investigational 
product will be destroyed at the site pe r institutional policy. It is the Investigator ’s responsibi lity 
to arrange for disposal of all empty containers, provided tha t procedures for proper disposal 
have been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of dis posal are kept.  
11.2 O
XALIPLATIN  
Oxaliplatin will be  supplied by the l ocal pharmacy using supply purcha sed from commercial 
sources.  
11.2.1 Toxicity  
The most common side effects of oxaliplatin include:  
• neutropenia, anemia, thrombocytopenia, hypertension, diarrhea, nausea, vomiting, 
constipation, oral mucositis,  abdominal pain, anorexia, fatigue, inj ection site reactions, 
alopecia and dehydration 
• Potentially serious toxicities include: 
• Grade 3/4 hypersensi tivity,  including anaphylactic/anaphylactoid reactions, to oxal iplatin 
has been o bserved in 2- 3% of colon c ancer patients. These reactions are usu ally managed  
with standard epinephrine, corticosteroid, antihistamine therapy, and require discontinuation of therapy  or desensitization protocol for continuation of therapy. 
• Peripheral sen sory neuropathy (acute ≤ 1 4 days and persist ent > 14 days) was reported in 
adjuvant patients treated with ELOXATIN as part of FOLFOX with a frequency of 92% 
(all grades) and 1 3% (gra de 3). At the 28-day follow- up after the last treatment cycle, 
60% of all patients had any grade (Gr ade 1=40%, Grade 2 =16%, Grade 3=5%) peripheral 
sensory neuropathy decreasing to 39% at 6-month follow-up (Grade 1=31%, Grade 
2=7%, Grade 3=1%) and 21% at 18  months of follow-up (Grade 1=17%, Grade 2=3%, 
Grade 3=1%).  
• Overall, neuropathy was reported in pati ents p reviously untre ated for advanced colorectal 
cancer in 82% (all grades) and 19% (grade 3/4), and in the previously treated patients in 74% (all grades)  and 7% (grade 3/4) events. Information regarding reversibility of 
neuropathy was not ava ilable from  the t rial for pat ients who had not been previously 
treated for colorectal cancer.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
57 • Reversible Posterior Leukoencephalopathy Syndrome (RPLS, also known as PRES, 
Posterior Reversible Encephalopathy Syndrome) has been observed in clinical trials (<  
0.1%) and postma rketing exper ience. Signs and symptoms of R PLS could be headache, 
altered mental functioning, seizures, abnormal vision from blurriness to blindness, associated or not with hypertension. Diagnosis of RPLS is based upon confirmation by brain imaging. 
• Pulmonary Toxi city. oxaliplatin has been associ ated with pulmonary fibrosis (<1% of 
study patients), which may be fatal. The combined incidence of cough and dyspnea was 7.4% (any grade) and < 1% (grade 3) with no grade 4 events in the oxaliplatin plus infusional 5-fluorouracil/leucovorin arm compared to 4.5% (any grade) and no grade 3 and 0.1% grade 4 events in the infusional 5- fluorouracil/leucovorin al one arm in 
adjuvant colon cancer patients. In this study, one patient died from eosinophi lic 
pneumonia in the oxalipla tin combination arm. The combined incidence of cough, 
dyspnea and hypoxia was 43% (any grade) and 7% (grade 3 and 4) in the oxaliplatin plus 5-fluorouracil/leucovorin arm compared to 32% (any grade) and 5% (grade 3 and 4) in the irinotecan plus 5-fluoroura cil/leucovorin arm of unknown dur ation for patients with 
previously untreated colorectal cancer. In case of unexplained respiratory sympto ms such 
as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, ELOXATIN should be discontinued until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis. 
• Hepatotoxicity as evidenced in the adjuvant study, by increase in transaminases (57% vs. 34%) and alkaline phosphatase (42% vs. 20 %) wa s observed m ore co mmo nly in the 
oxaliplatin combination arm than in the control arm. The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alter ation s, perisinusoidal fib rosis, and veno-
occlusive lesi ons. Hepatic vascular disorders should be considered, and if appropriate, 
should be investigated i n case of abnormal liver function test results or portal 
hypertension, which cannot be explained by li ver m etastases  
11.2.2 Formulation 
11.2.2.1 Powder 
ELOXATIN i s supplied in single-use vials containing 50 mg or 100 mg of oxaliplatin as a 
sterile, preservative -free lyophilized powder for reconstitution. Lactose monohydrate is also 
present as an inactive ingredient.  
11.2.2.2 Solution 
ELOXATIN is s upplied in single- use vials  containing 50 mg, 100 mg or 200 mg of oxaliplatin as 
a sterile, preservative -free, aqueous solution at a conc entrati on of 5 mg/ml. Water for Injection, 
USP is present as an inactive ingredient. 
11.2.3 Preparation  
11.2.3.1 Powder 
Reconstitution or fin al dilution must neve r be perform ed with a sodium chloride solution or other 
chloride containing solutions. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
58 The lyophilized powder is reco nstituted by adding 10 mL (for the 50 mg vial) or 20 mL (for the 
100 mg vial) of Water fo r Inje ction , USP or 5% Dextrose Injection, USP. Do not adminis ter the 
reconstituted solution without further dilution. The reconstituted solution must be further dilut ed 
in an infusion solution of 250-500 mL of 5% Dextrose Injection, USP. 
After reconstitution in the original vial, the so lution may be stored up to 24 hours under 
refrigeration [2 -8°C (36 -46°F)]. After final dilution with 250-500 mL of 5% Dextrose I njectio n, 
USP, the shelf life is 6 hours at room temperature [20-25°C (68-77°F)] or up to 24 hours under 
refrigeration [2 -8°C (36-46°F)]. 
ELOXATIN is not light sensitive.  
11.2.3.2 Solution 
Do not freeze and protect from light the concentrated solution. 
A final dilution mu st never be performed with a sodium chloride solution or other chloride 
containing solutions. The so lution must be further diluted in an infusion solution of 250-500 mL of 5% Dextrose 
Injection, USP. After dilution with 250-500 mL of 5% Dextrose Inj ection,  USP, the shelf life is 6 hours at room 
temperature [20 -25°C (68 -77°F)] or up to 24 hours under refrigeration [2- 8°C ( 36-46°F)].  
After fina l dilution, protection from light is not required. 
ELOXATIN is incompatible in solution with alkaline medications or media (such as basic 
solutions of 5-fluorouracil) and must not be mixed with these or adm iniste red s imultaneously 
through the same infusion  line. The infusion line should be flushed with 5% Dextrose Injection, 
USP prior to administration of any conc omitant medication.  
11.2.4 General  
Parenteral drug products should be inspected visually for particulat e matter an d discoloration 
prior to administration  and discarded if present.  
Needles or intravenous administration sets containing aluminum parts that may come in cont act 
with oxaliplatin should not be used for the preparation or mixing of the drug. Aluminum has been  reported to  cause degradation of platinum compounds.  
11.2.5 Stability and Storage  
Powder for solution for infusion: 
Store under normal lighting conditions at 25°C (77°F); excursions permitted to 15-30°C (59-
86°F). 
Concentrate for solution for infusion: Store at 25°C (77°F) ; excu rsions permitted to 1 5-30°C (59-86°F). Do not freeze and protect from 
light (keep in original outer carton). 11.2.6 Administration procedures  
Please see section  3.3.2.2. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
59 11.2.7 Incompatibilities   
No spe cific cytochrome P-450- based drug interaction studies have been conducted. No 
pharmacokinetic interaction between 85 mg/m2 oxaliplatin and 5-fluorouracil/leucovorin has 
been observed in patients treated every 2 weeks. Increases of 5 -fluorouracil plas ma 
concentr ations by approxim ately 20% have been observed with doses of 130 mg/m2 oxaliplatin 
dosed every 3 weeks. Because platinum- containing species are elimi nated p rimarily through the 
kidney, clearance of these products may be decreased by co- administr ation of potentially 
nephrotoxic compounds; although, this has not been specifically studied. 
11.3 CAPECITABINE   
Chemical Name: 5’ -deoxy -5-fluoro -N-[(pentyloxy) carbonyl]-cytidine  
Other Names: xeloda  
Classification: Fluoropyrimidine carbamate  
M.W.: 359.35 11.3.1 Source  
Capecitabine will be su pplied by the local pharmacy using supply purchased from commercial 
sources.  
11.3.2 Toxicity  
Most common adverse reactions (≥30%) were di arrhea,  hand- and-foot syndrome, nausea, 
vomiting, abdominal pain, fatigue/weakness, and hyperbilirubinemia.  Other adverse reactions, 
including serious adverse reactions, have been reported. 
Pooled Phase 3 Colorec tal Trials: Percent Incidence of Adverse Reactions in  ≥5% of 
Patients  
Advers e Event Capecitabine  (n=596 ) 
 Total 
% Grade 3 
% Grade 4 
% 
Number of Patie nts With > One Adverse Event 96 52 9 
Body Syste m/Advers e Event    
GI 
55 13 2 Diarrhe a 
Nausea 43 4 – 
Vomiting 27 4 <1 
Stomatitis 25 2 <1 
Abdominal Pain 35 9 <1 
Gastrointestinal Motility Disorde r 10 <1 – 
Constipation 14 1 <1 
Oral Discomfort 10 – – 
Upper GI Inflammatory Disorder s 8 <1 – 
Gastrointestinal Hemorrhage  6 1 <1 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
60 Advers e Event Capecitabine  (n=596 ) 
 Total 
% Grade 3 
% Grade 4 
% 
Number of Patie nts With > One Adverse Event 96 52 9 
Body Syste m/Advers e Event    
Ileus 6 4 1 
Skin and Subcutaneous  
54 17 NA Hand-and-Foot Syndro me 
Dermatitis 27 1 – 
Skin Discoloration 7 <1 – 
Alopec ia 6 – – 
Genera l 
42 4 – Fatigue/Weaknes s 
Pyrex ia 18 1 – 
Edema 15 1 – 
Pain 12 1 – 
Chest Pain 6 1 – 
Neuro logical 
10 – – Periphera l Sensor y Neuropa thy 
Headach e 10 1 – 
Dizziness* 8 <1 – 
Insomnia 7 – – 
Taste Disturbanc e 6 1 – 
Metabolism 
26 3 <1 Appetite Decrease d 
Dehydra tion 7 2 <1 
Eye 
13 – – Eye Irritation 
Vision Abnor mal 5 – – 
Respiratory 
14 1 – Dyspne a 
Cough 7 <1 1 
Pharyngea l Disorde r 5 – – 
Epistaxis 3 <1 – 
Sore Throat 2 – – 
Muscu loske letal 
10 2 – Back Pain 
Arthralgia 8 1 – 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
61 Advers e Event Capecitabine  (n=596 ) 
 Total 
% Grade 3 
% Grade 4 
% 
Number of Patie nts With > One Adverse Event 96 52 9 
Body Syste m/Advers e Event    
Vascu lar 
Venou s Thro mbosis  
8  
3  
<1 
Psychiatric  
5  
–  
– Mood Alteration 
Depress ion 5 – – 
Infec tions 
Viral  
5  
<1  
– 
Blood and Lymphatic 
80 2 <1 Anemia 
Neutropen ia 13 1 2 
Hepatobiliar y 
Hyperb ilirubinemia 48 18 5 
– Not observe d 
* Excluding vertigo 
NA = Not A pplicabl e 
11.3.3 Formulation and preparation  
Tablets: 150 mg and 500 mg  
XELODA is supplied as biconvex, oblong film- coated tablets for oral administration. Each light 
peach -colore d tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 
mg capecitabine. The inact ive ingredients in XELODA include: anhydrous lactose, 
croscarmellose sodium, hydroxypropyl methylcellulos e, microcrystalline cellulose, magnesium 
stearate and purified water. The peach or light peach film coating contains hydroxypropyl 
methylcel lulose , talc, titanium dioxid e, and synthetic yellow and red iron oxides. 
11.3.4 Stability and Storage  
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). KEEP TIGHTLY 
CLOSED.  
Care should be exercised in the handling of XELODA. XELODA tablet s should not be cut or 
crushed. Procedures for the proper handling and disposal of anticancer drugs should be considered. Any unused product should be disposed of in accordance with local requirements, or drug take back programs. Several guidelines on the subjec t hav e been published. 
11.3.5 Administration procedures  
Please see section 3.3.2.1 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
62 11.3.6 Incompatibilities   
• Anticoagulants: Monitor anticoagulant response (INR or prothrombin time) frequently in 
order to adjust the ant icoagu lant dose as needed. 
• Phenytoin: Monitor phenytoin levels in patients taking XELODA concomitantly with 
phenytoin. The phenytoin dose may need to be reduced. 
• Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.  
• CYP2C9 substr ates: Care should be exercised when XELODA is co -administered with 
CYP2C9 substrates.  
• Food reduced both the rate and extent of absorption of capecitabine.  
.  
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
63  
12 REFERENCES  
1. Jemal, A., et al., Cancer stati stics,  2009. CA Cancer J Clin , 2009. 59(4): p. 225-49. 
2. Duffy, A., et al., Gallbladder cancer (GBC): 10- year exper ience at Memorial Sloan-
Kettering Cancer Cen tre (MSKCC).  J Surg Oncol, 2008. 98(7): p. 485-9. 
3. Valle, J., et al., Cisplatin plus gemcitabi ne ver sus g emcitabine for bil iary tract cancer.  N 
Engl J Med, 2010. 362(14): p. 1273-81. 
4. Lamarca, A., et al., Second-line chemotherapy in advanced biliary cancer: a systematic 
review.  Ann Oncol, 2014. 25(12): p. 2328-38. 
5. Kantoff, P.W., et al., Sipule ucel-T immu notherapy for castration-resistant pros tate 
cancer.  N Engl J Med, 2010. 363(5): p. 411-22. 
6. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic 
melanoma. N Engl J Med, 2010. 363(8): p. 711-23. 
7. Robert, C., et al., Ipi limum ab plus dacarbazine for previously untr eated metastatic 
melanoma. N Engl J Med, 2011. 364(26): p. 2517-26. 
8. Hanahan, D. and R.A. Weinberg, Hallmark s of cancer: the next generation.  Cell, 2011. 
144(5): p. 646-74. 
9. Brahmer, J.R., et al., Safety and activity of anti- PD-L1 antibody in patients with 
advanced cancer. N Engl J Med. 366(26): p. 2455-65. 
10. Topalian, S.L., et al., Safety, activity, and imm une correl ates of anti- PD-1 antibody in 
cancer.  N Engl J Med. 366(26): p. 2443-54. 
11. Chung, K.Y., et al.,  Phase II study of the anti- cytotoxic T -lymphocyte-associated antigen 
4 monoclonal antibody, tremelimumab, in patients with refractory metastatic col orectal 
cancer.  J Clin Oncol, 2010. 28(21): p. 3485-90. 
12. Royal, R.E., et al., Phase 2 trial of sing le ag ent Ipilimumab (anti- CTLA -4) for locall y 
advanced or metastatic pancreatic adenocarcinoma. J Immunother, 2010. 33(8): p. 828-33. 
13. Park, S.H., et al., Phase 1b Trial of Biweekly Intravenous Pexa- Vec (JX -594), an 
Oncolytic and Immunotherapeutic Vacci nia Virus in Colorectal Cancer.  Mol Ther, 2015. 
23(9): p. 1532-40. 
14. El-Khoueiry, A.B., et al., Phase I/II s afety and antitumor activity of nivolumab in patients 
with advanced hepatocellular carcinoma (HCC): CA209-040. ASCO Meeting Abstracts, 2015. 33(18 _suppl): p. LBA101. 
15. Desrichard, A., A. Snyder, and T.A. Chan, Cancer Neoantigens and Applications for 
Immu notherapy. Clin Cancer Res, 2015. 
16. Snyder, A., et al., Genetic basis for clinical response to CTLA-4 blockade in melanoma. 
N Engl J Med, 2014. 371(2 3): p. 2189-99. 
17. Rizvi, N.A., et al., Cancer immunology. Mutational landscape determines sensitivity to 
PD-1 blockade in non-small cell lung cance r. Science, 2015. 348(6230): p. 124-8. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
64 18. Shimomura, A., et al., Tremelimumab -associated tumor regres sion following after initial 
progression: two case reports. Immunotherapy, 2016. 8(1): p. 9-15. 
19. Y.J. Bang, T.D., F. De Braud, S. Piha-Paul, A. Hollebecque, A.R. Abdul Razak, C.C. 
Lin, P.A. Ott, A.R. He, S.S. Yuan, M. and B.L. Koshiji, R. Aggarwal. Safe ty and efficacy 
of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: 
Interim  
resul ts of KEYNOTE -028. in European Cancer Congress 2015. 2015. 
20. Trinchieri, G., Inflammation in cancer: a therapeutic target? Oncology (Williston P ark), 
2011. 25(5): p. 418-20. 
21. Trinchieri , G., Cancer and inflammation: an old intuition with rapidly evolving new 
concepts.  Annu Rev Immunol, 2012. 30: p. 677-706. 
22. Ghouri, Y.A., I. Mian, and B. Blechacz, Cancer review: Cholangiocarcinoma. J 
Carcino g, 2015. 14: p. 1. 
23. Tazuma, S. and G. Kaj iyama, Carcinogenesis of malignant lesions of the gall bladder. 
The impact of chronic inflammation and gallstones.  Langenbecks Arch Surg, 2001. 
386(3): p. 224-9. 
24. Rizvi, S. and G.J. Gores, Pathogenesis, diagnosis, and management of 
cholangiocarcinoma. Gastroenterology, 2013. 145(6): p. 1215-29. 
25. Chang, J.S., C.R. Tsai, and L.T. Chen, Medical risk factors associated with 
cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One, 2013. 8(7): p. e69981. 
26. El-Serag, H.B., et al., Ris k of hepatobiliary and pancreatic cancers after hepatitis C virus 
infection: A population-based study of U.S. veterans.  Hepatology, 2009. 49 (1): p. 116-23. 
27. West, J., et al., Trends in the incidence of primary  liver and biliary trac t cancers in 
England and Wales 1971-2001. Br J Cancer, 2006. 94(11): p. 1751-8. 
28. Oshiro, Y., et al., Inflammation-based prognost ic score i s a useful predictor of 
postoperative outcome in patients with extrahepatic cholangiocarcinoma.  J Hepatobiliary 
Pancreat Sci, 2013. 20(3 ): p. 389-95. 
29. Schrumpf, E., et al., The biliary epithelium presents antigens to and activates natural 
killer T cells . Hepatology, 2015. 62(4): p. 1249-59. 
30. Liaskou, E., et al., High -throughput T- cell recep tor sequencing across c hronic liver 
diseases  reveals distinct disease -associated repertoires.  Hepatology, 2015. 
31. Shaib, Y.H., et al., Risk factors of intrahepatic cholangiocarcinoma in the United States: 
a case-control study. Gastroenterology, 2005. 128(3): p. 620-6. 
32. Liaskou, E., et al., Loss of CD28 expression by liver- infiltrating T cells contributes to 
pathogenesis of primary sclerosing cholangiti s. Gastroenterology, 2014. 147(1): p. 221-
232 e7. 
33. Tran, E., et al., Cancer immunotherapy based on mutation- specific CD4+ T cells in a 
patient with epithelial cancer.  Science, 2014. 344(6184): p. 641-5. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
65 34. Nakamura, H., et al., Genomic spectra of biliary tract cancer.  Nat Genet, 2015. 47(9): p. 
1003-10. 
35. Le, D.T., et al., PD -1 Blockade in Tumors wit h Mis match -Repair Defic iency.  N Engl J 
Med, 2015. 372(26): p. 2509-20. 
36. Thomas, N.E., et al., Tumor- infiltr ating lymphocyte grade in primary melanomas is 
independently associated with melanoma-specific survival in the population-based genes, 
envir onment and melanoma study. J Clin Oncol, 2013. 31(33): p. 4252-9. 
37. Seo, A.N., et al., Tumour- infiltrating CD8+ ly mphocytes as an independent predictive 
facto r for pathological complete response to primary systemic therapy in breast cancer. 
Br J Cancer, 2013. 109(1 0): p. 2705-13. 
38. Schalper, K.A., et al., Objective measurement and clinical significance of TILs in non-
small cell lung cancer. J Natl Cancer Inst , 2015. 107(3).  
39. Kluger, H.M., et al., Characterization of PD-L1 Expression and Associated T- cell 
Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer 
Res, 2015. 21(13): p. 3052-60. 
40. Galon, J., et al., Type, density, and location of immune cells within human colorectal 
tumors predict clinical outcome. Science, 20 06. 31 3(5795): p. 1960-4. 
41. Mlecnik, B., et al., Histopathologic-based prognostic factors of colorectal cancers ar e 
associated with the state of the local imm une reacti on. J Clin Oncol, 2011. 29(6): p. 610-
8. 
42. Tewari, N., et al., The presence of tumour- associate d lymphocytes confers a good 
prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.  BMC Cancer, 2013. 13: p. 436. 
43. Tran, E., et al., Immunogenicity of somatic mutations in human gastrointestinal cancers.  
Scien ce, 2015. 
44. Sabb atino, F., et al., PD -L1 and HLA Class I Antigen Expression and Clinical Course of 
the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res, 2015. 
45. Nakakubo, Y., et al., Clinical significance of immune cell infiltration within gallbladder 
cancer.  Br J Cancer, 2003. 89(9): p. 1736-42. 
46. Goeppert, B., et al., Prognostic impact of tumour- infiltrating immune cells on biliary 
tract cancer.  Br J Cancer, 2013. 109(10): p. 2665-74. 
47. Zhuo, C., et al., FOXP3+ Tregs: heterogeneous phen otypes and conflicting impacts on 
survi val outcomes in patients with colorectal cancer. Immunol Res, 2015. 61(3): p. 338-
47. 
48. Ma, C., et al., Down regulation of FOXP3 inhibits invasion and immune escape in 
cholangiocarcinoma. Biochem Biophys R es Com mun, 2015. 458(2): p. 234-9. 
49. Cardinale, V., et al., Intra -hepatic and extra-hepatic cholangiocarcinoma: New insight 
into epidemiology and risk factors. World J Gastrointest Oncol, 2010. 2(11): p. 407-16. 
50. Guedj, N., et al., Comparative protein expression  profiles of hilar  and peripheral hepat ic 
cholangiocarcinomas. J Hepatol, 2009. 51(1): p. 93-101. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
66 51. Cam poli, M. and S. Ferrone, HLA antigen changes in malignant cells: epigenetic 
mechanisms and biologic significance. Oncogene, 2008. 27(45): p. 5869-85. 
52. Campoli, M. and S. Ferrone, Tumor escape mechanisms: potential role of soluble HLA 
antigens and NK cells activating ligands. Tissue Antigens, 2008. 72(4): p . 321-34. 
53. Ryschich, E., et al., Control of T- cell-mediated immune response by HLA class I in 
human pancreatic carcinoma. Clin Cancer  Res, 2005. 11(2 Pt 1): p. 498-504. 
54. Du, C. and Y. Wang, The immunoregulatory mechanisms of carcinoma for i ts surviva l 
and development. J Exp Clin Cancer Res, 2011. 30: p. 12. 
55. Kasajima, A., et al., Down- regulation of the antigen processing machinery is linked to a 
loss of inflammatory response in colorectal cancer. Hum Pathol, 2010. 41(12): p. 1758-
69. 
56. Goeppert, B., et al., Major histocompatibility complex class I expression impacts on 
patient sur vival and type and density of immune cells in biliary tract cancer.  Br J Cancer, 
2015. 113(9): p. 1343-9. 
57. Taube,  J.M., et al., Differential Expression of Im mune-Regulatory Genes Associated with 
PD-L1 Display in Melanoma: Implications for PD-1 Pathway B lockade.  Clin Cancer 
Res, 2015. 21(17): p. 3969-76. 
58. Ye, Y., et al., Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 
on tumor- infiltr ating T ce lls as a mechanism of immune evasion. J Surg Oncol, 2009. 
100(6): p. 500-4. 
59. Brahmer, J.R., et al., Safety and activity of anti- PD-L1 antibody in patients with 
advanced cancer. N Engl J Med, 2012. 366(26): p. 2455-65. 
60. Topalian, S.L., et al., Safety,  activity, and immune correlates of anti- PD-1 antibody in 
cancer.  N Engl J Med, 2012. 366(26): p.  2443-54. 
61. Mark s, E.I. and N.S. Yee, Immunotherapeutic approaches in biliary tract carcinoma: 
Current status and emerging strategies. World J Gast rointest O ncol, 2015. 7(11): p. 338-
46. 
62. Kaida, M., et al., Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemci tabine 
combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother, 2011. 34 (1): p. 92-9. 
63. Yamamoto, K., et al., MUC1 peptide vaccination in patients with advanced pancreas or 
biliary tract cancer.  Anticancer Res, 2005. 25(5): p. 3575-9. 
64. Aruga, A., et al., Phase I clinical trial of multiple -peptide vaccination for patients with 
advanced biliar y tract cancer.  J Transl Med, 2014. 12: p. 61. 
65. Aruga, A., et al., Long- term Vaccination with  Multiple Peptides Derived fr om Cancer-
Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. C lin Cancer  Res, 2013. 19(8): p. 2224-31. 
66. Kobayashi, M., et al., Dendritic cell-based immunotherapy targeting synthesized peptides 
for advanced biliary tract cancer. J Gastrointest Surg, 2013. 17(9): p. 1609-17. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
67 67. Lepisto, A.J., et al., A phase I/II s tudy of a MUC1 peptide pulsed autologous dendritic 
cell vaccine as adjuvant therapy in patients with r esect ed pancreatic and biliary tumors.  
Cancer Ther, 2008. 6(B): p. 955-964. 
68. Duffy, A.G. and T.F. Greten, Immunological off-target effects of standard treatments  in 
gastrointestinal cancers. Ann Oncol, 2014. 25(1): p. 24-32. 
69. Liu, W.M., et al., Pre -treatment with chemotherapy can enhance the antigenicity and 
immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer, 2010. 
102(1): p . 115-23. 
70. Burris, H. and A.M. Storniolo, Assessing clinical benefit in the treatment of panc reas 
cancer: gemcitabine comp ared to 5-fluorouraci l. Eur J Cancer, 1997. 33 Suppl 1 : p. S18-
22. 
71. Koido, S., et al., Immunogenic modulation of cholangiocarcinoma cells by 
chemoimmunotherapy. Anticancer Res, 2014. 34(11): p. 6353-61. 
72. Greten, T.F. and F. Korangy, Radiofrequency ablation for the treatment of HCC --maybe 
much more than simple tumor destruction? J Hepat ol, 2010. 53(4): p. 775-6. 
73. den Brok, M.H., et al., Efficient loading of dendritic cells following cryo and 
radiofrequency ablation in combination with immune modulation induces anti- tumo ur 
immunity.  Br J Cancer, 2006. 95(7): p. 896-905. 
74. Zerbini, A., et al., Radiofrequency thermal ablation of hepatocellular carcinoma liver 
nodules can activate and enhance tumor- specific T -cell responses . Cancer Res, 2006. 
66(2): p.  1139-46. 
75. Zerbini, A., et al., Increased immunostimulatory activity conferred to antigen -presenting 
cells by exposure to antige n extract from hepatocellular carcinoma after radiofrequency 
thermal ablation. J Immunother, 2008. 31( 3): p. 271-82. 
76. Hans ler, J., et al., Acti vation and dramatically increased cytolytic activity of tumor 
specific T lymphocytes after radio -frequency ablation in patients with hepatocellular 
carcinoma and colorectal liver metastases. World J Gastroenterol, 2006. 12 (23): p. 3716-
21. 
77. Hiroishi, K., et al., Strong CD8(+) T-cell responses against tumor-associated antigens 
prolong the recurrence- free interval after tu mor treatment in patients with hepatocellular 
carcinoma. J Gastroenterol, 2010. 45(4):  p. 451-8. 
78. Johnson, E.E., et al., Radiofrequency ablation combined with KS-IL2 immunocytokine 
(EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res, 2009. 15(15): p. 4875-84. 
79. Nijkamp, M.W., et al., Radi ofreq uency ablation of colorectal liver meta stases induces an 
inflammatory response in distant hepatic metastases but not in local accelerated outgrowth. J Surg Oncol, 2010. 101(7): p. 551-6. 
80. Duffy, A.G., et al., A pilot study of tremelimumab - a monoclonal antibody against 
CTLA -4 - in combination with either trans catheter arterial chemoembolization (TACE) 
or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). ASCO Meeting Abstracts, 2015. 33(15 _suppl): p. 4081. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
68 81. Weber, J. S., K.C. Kahler, and A. Hauschild, Management of immune- related adverse 
events and kinetics of response with ipilimumab. J Clin Oncol, 2012. 30(21): p. 2691-7. 
82. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: Re vised 
RECIST guideline (version 1.1). European Journal of Cancer, 2009. 45 (2): p. 228-247. 
83. Rustin, G.J.S., et al., Re: New guidelines to evaluate the response to treatment in solid 
tumors (ovarian cancer).  Journal of the National Cancer Institute, 2004. 96 (6): p. 487-
488. 
84. Bubley, G.J., et al., E ligibility and response guidelines for phase II clinical trials in 
androgen-independent prostate cancer: Recommendations from the prostate- specific 
antigen working group. Journal of Clinical Oncology, 1999. 17(11 ): p. 3461-3467. 
85. Scher, H.I., et al., De sign and end points of clinical trials for patients with progressive 
prostate cancer and castrate levels of testostero ne: Recommendations of the prostate 
cancer clinical trials working group. Journal of Clini cal Oncology, 2008. 26 (7): p. 1148-
1159. 
86. Vergote, I., et al., Re: New guidelines to evaluate the response to treatment in solid 
tumors [ovarian cancer].  Journal of the National Cancer Institute, 2000. 92 (18): p. 1534-
1535. 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
69 13 APPENDICE S 
13.1 APPENDIX A-P ERFORMANCE STATUS CRITERIA  
ECO G Performance Status Scale 
Grade  Descriptions 
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory. 
Restricted in physic ally strenuous 
activity, but ambulatory and able  
to carry  out work of a light or 
sedentary nature (e.g., light 
housework, office work).  
2 In bed <50% of the time. 
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours. 
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of waking hours. 
4 100% bedridden. Completely 
disabled. Cannot carry on any 
self-care.  Totally confined to bed 
or chair . 
5 Dead.  
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
70 13.2 APPENDIX B- MODIFIED IMMUNE -RELATED RESPONSE CRITERIA (IRRC) 
This new classification is based on the recent learning from clinical studies with cancer 
immunotherapies that even if some new lesion s appear at t he beginning of a treatment or if t he 
total tumor burden does not increase substantially, tumor regressions or stabilizations might still 
occur later. The irRC were created using bi -dimensional measurements (as previously widely 
used in the World Health Or ganization criteria). For this tria l, the concepts of the irRC are 
combined with RECIST 1.1 to come up with the modified irRC.  
For modified irRC, only target and measurable lesions are taken into account. In contrast to the 
RECIST 1.1 criteri a, the modifi ed irRC criteria (a) require confirmation of both progression and 
response by imaging at 6 weeks after initial imaging and (b) do not necessarily score t he 
appearance of new lesions as progressive disease if the sum of lesion diameters of targ et lesions 
(minimum of 10 mm per lesion, maximum of 5 target lesions, maximum of 2 per organ) and 
measurable new lesions do es not increase by ≥ 20%.  
The same method of assessment and the same technique should be used to characterize each  
identified and re ported target  lesion(s) at baseline, during the trial, and at the end of trial visit. 
All measurements should be recorded i n metric notation. The modified irRC based on RECIST 
1.1 are displayed below.  
 
 
 
  
 
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
71  
Overall Responses Derived from Changes in Index,  Non -Inde x, and New Lesions  
 
 
Abbreviated Title: CAPOX P embrolizumab in BTC  
Version Date: 03/19/2020  
72 13.3 APPENDIX C PATIENT’S  MEDICATION  DIARY  ________________________  
Cycle___________________ 
Patient’s ID ___________________ INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for  each cycle of treatme nt 
2. You wi ll take capecitabine _________mg tw ice a day . You should take the tablets with food at 
approximately the same time each day.  
3. Dose: ____________150 mg  ______________ 500 mg 
4. Record the date, the number of tablets that you took, and when you too k them. 
5. If you have any comments or notice any s ide effec ts, please record them in the comments column.  
6. Please bring this f orm and your bottles of capecitabine when you come for your clinic visits. 
Day Date  Time of 
AM 
Dose  # of Tablets Taken  
150 mg       500mg Time o f 
PM 
Dose  # of Tablets Taken 
150 mg       500mg  Comments  
1         
2         
3         
4         
5         
6         
7         
8         
9         
10         
11         
12         
13         
14         
Patient’s signature:     ___________________________________________________ 